Track market-moving stories before they get noisy

Bitcoin sitting idle in a wallet earns nothing. Stacks has a pitch for changing that, and it comes with real BTC attached.

The Stacks network is launching a 90-day incentive program designed to pull users deeper into its Bitcoin-native DeFi ecosystem. The program distributes 1 BTC per month, totaling 3 BTC across the full run, paid directly to participants as rewards for borrowing the stablecoin USDCx or supplying liquidity to USDCx trading pairs.

The program kicks off around September 10, 2026, timed to Bitcoin block 966,350.

What participants actually do to earn rewards Users who borrow USDCx against sBTC or STX collateral qualify for a share of the monthly BTC distribution. So do users who add liquidity to USDCx trading pairs on the network.

Advertisement

sBTC is a 1:1 Bitcoin-backed asset native to the Stacks ecosystem, meaning one sBTC is always redeemable for one Bitcoin. Using it as collateral to borrow a stablecoin is essentially the same move institutional desks have been running with wrapped Bitcoin on Ethereum for years, just executed within the Stacks environment and rewarded with more BTC on top.

STX, the native token of the Stacks blockchain, also qualifies as collateral. That makes the program accessible to users who are already active in the Stacks ecosystem without necessarily holding sBTC.

Two protocol partners are running the operational infrastructure. Zest Protocol handles the lending and borrowing side, processing USDCx loans against collateral. Bitflow, a decentralized exchange built on Stacks, manages the liquidity side, where users pair USDCx with other assets to deepen on-chain trading markets.

The USDCx layer underneath it all USDCx is the stablecoin sitting at the center of this program, and it is relatively new. Stacks launched USDCx in December 2025, building it on top of Circle’s xReserve infrastructure. The backing is USDC, which itself maintains a 1:1 peg to the US dollar.

Rather than creating an entirely novel stablecoin from scratch, Stacks wrapped institutional-grade dollar infrastructure in a form that operates natively within the Bitcoin layer 2 environment. The result is a stablecoin that inherits USDC’s credibility while functioning inside a Bitcoin-secured network.

The strategic logic behind paying rewards in BTC Choosing to pay rewards in BTC rather than STX tokens is a deliberate design choice. Token-denominated reward programs have a built-in problem: the more users farm them, the more sell pressure hits the reward token, which erodes the value of future rewards in a self-defeating loop. Stacks sidesteps that entirely by paying out in Bitcoin, an asset participants presumably already want more of regardless of what the protocol’s native token is doing.

The total reward pool is 3 BTC across 90 days, with 1 BTC distributed every 30 days rather than front-loaded.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

, /PRNewswire/ -- Weyerhaeuser Company (NYSE: WY) today announced that its board of directors declared a quarterly base cash dividend of $0.21 per share on the common stock of the company, payable in cash on September 18, 2026, to holders of record of such common stock as of the close of business on September 4, 2026.

Under Weyerhaeuser's cash return framework, the company expects to supplement its quarterly base cash dividend, as appropriate, with an additional return of variable cash to achieve a targeted total return to shareholders of 75 to 80 percent of annual Adjusted Funds Available for Distribution (Adjusted FAD). The company has the flexibility in its capital allocation framework to return this additional cash in the form of a supplemental cash dividend, opportunistic share repurchases, or a combination of the two.

Adjusted FAD, a non-GAAP measure, is defined by Weyerhaeuser as net cash from operations adjusted for capital expenditures and significant non-recurring items.

ABOUT WEYERHAEUSER
Weyerhaeuser Company, one of the world's largest private owners of timberlands, began operations in 1900 and today owns or controls more than 10 million acres of timberlands in the U.S., as well as additional public timberlands managed under long-term licenses in Canada. Weyerhaeuser has been a global leader in sustainability for more than a century and manages 100 percent of its timberlands on a fully sustainable basis in compliance with internationally recognized sustainable forestry standards. Weyerhaeuser is also one of the largest manufacturers of wood products in North America and operates additional business lines around product distribution, climate solutions, real estate, energy and natural resources, among others. In 2025, the company generated $6.9 billion in net sales and employed approximately 9,500 people who serve customers worldwide. Operated as a real estate investment trust, Weyerhaeuser's common stock trades on the New York Stock Exchange under the symbol WY. Learn more at www.weyerhaeuser.com.

FORWARD-LOOKING STATEMENTS
This news release contains statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the amount, timing and occurrence of future quarterly and supplemental cash dividends as well as the company's dividend framework and future share repurchases. Forward-looking statements are generally identified by words such as "expects" and "targeted," references to events occurring on specified future dates and other words and expressions referencing future events or occurrences. All forward-looking statements are based on our current expectations and assumptions and are not guarantees of future events or performance. The realization of our expectations and the accuracy of our assumptions are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in our 2025 Annual Report on Form 10-K, as well as those set forth from time to time in our other public statements, reports, registration statements, prospectuses, information statements and other filings with the SEC, and other factors not described herein or elsewhere because they are not currently known to us or because we currently judge them to be immaterial.  It is not possible to predict or identify all risks and uncertainties that might affect the accuracy of our forward-looking statements and, consequently, our descriptions of such risks and uncertainties should not be considered exhaustive. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Also included in this news release are references to Adjusted FAD, which is a non-GAAP financial measure. Adjusted FAD may not be comparable to similarly named or captioned non-GAAP financial measures of other companies due to potential inconsistencies in how such measures are calculated. Adjusted FAD should not be considered in isolation from, and is not intended to represent an alternative to, our GAAP results.

For more information contact:
Analysts – Andy Taylor, 206-539-3907
Media – Nancy Thompson, 919-861-0342

SOURCE Weyerhaeuser Company

Gossamer Bio (GOSS - Free Report) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced a loss of $0.2, delivering a surprise of -17.65%.

Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

Gossamer Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $9.24 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 171.71%. This compares to year-ago revenues of $11.49 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Gossamer Bio shares have lost about 94.3% since the beginning of the year versus the S&P 500's gain of 13.2%.

What's Next for Gossamer Bio?While Gossamer Bio has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Gossamer Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.07 on $5.4 million in revenues for the coming quarter and -$0.39 on $34.8 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the broader Zacks Medical sector, Veeva Systems (VEEV - Free Report) , is yet to report results for the quarter ended July 2026. The results are expected to be released on August 26.

This provider of cloud-based software services for the life sciences industry is expected to post quarterly earnings of $2.22 per share in its upcoming report, which represents a year-over-year change of +11.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Veeva Systems' revenues are expected to be $904.07 million, up 14.6% from the year-ago quarter.

DLocal (DLO - Free Report) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -10.00%. A quarter ago, it was expected that this online payment company would post earnings of $0.16 per share when it actually produced earnings of $0.17, delivering a surprise of +6.25%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

DLocal, which belongs to the Zacks Financial Transaction Services industry, posted revenues of $399.66 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 11.07%. This compares to year-ago revenues of $256.46 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

DLocal shares have added about 1% since the beginning of the year versus the S&P 500's gain of 13.2%.

What's Next for DLocal?While DLocal has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for DLocal was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.22 on $385.49 million in revenues for the coming quarter and $0.82 on $1.51 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial Transaction Services is currently in the top 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Klarna (KLAR - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 18.

This Swedish buy now, pay later company is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Klarna's revenues are expected to be $987.94 million, up 20% from the year-ago quarter.

Today's Change

(

-8.40

%) $

-10.41

Current Price

$

113.47

Cisco Systems (CSCO -8.40%), a global networking hardware and security provider, closed at $113.47, down 8.40%. The stock fell after better-than-expected fiscal fourth-quarter results and guidance, but investors are focusing on margin pressure, even as the stock is still up nearly 50% this year.
Trading volume reached 61.1 million shares, coming in about 137% above its three-month average of 25.7 million shares.

How the markets moved todayThe S&P 500 (^GSPC +0.65%) rose 0.65% to 7,799, and the Nasdaq Composite (^IXIC +0.81%) gained 0.81% to 26,803. In networking equipment and enterprise communications technology, Arista Networks (ANET -3.27%) fell 3.27% to $203.62, while Hewlett Packard Enterprise (HPE +1.75%) rose 1.75% to $59.82 as investors weighed Cisco Systems' earnings reaction and broader spending trends.

What this means for investorsInvestors approached Cisco’s fiscal fourth-quarter earnings with high expectations for the company. Cisco stock was up 60% year-to-date entering today’s trading. While the company delivered record top and bottom-line results, total (non-GAAP) gross margin for the quarter dropped to 66.3% from last year's 68.4%. This decline was partly attributed to the increased cost of components used in AI hardware, such as memory.

AI-related demand remains strong, however. Some analysts also noted the decline in gross margin, but suggested that operating margins would expand in fiscal 2027. This expansion could result in profits growing faster than revenue.

That may make today’s plunge a good opportunity to at least begin a position in Cisco stock.

Howard Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Arista Networks, Cisco Systems, and Hewlett Packard Enterprise. The Motley Fool has a disclosure policy.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.1 Full approval for this indication will be contingent upon verification and description of clinical benefit in the confirmatory trial(s). ZENBEXUS is the first FDA-approved CELMoD, belonging to a new class called cereblon-modulating protein degraders for the treatment of multiple myeloma.1 Please see the Important Safety Information section below, including Boxed WARNINGS for ZENBEXUS regarding embryo-fetal toxicity and venous and arterial thromboembolism. ZENBEXUS is contraindicated in females who are pregnant.1

$BMY announced @US_FDA granted accelerated approval for its first CELMoD in relapsed or refractory #MultipleMyeloma, introducing a new class of treatment.

Share “Today’s approval of ZENBEXUS represents meaningful progress for patients living with multiple myeloma and underscores the power of our targeted protein degradation platform, particularly our CELMoD programs,” said Cristian Massacesi, MD, chief medical officer and head of development at Bristol Myers Squibb. “As the first approved CELMoD, ZENBEXUS marks the arrival of a new treatment class and is an important milestone in our efforts to expand what is possible for patients with multiple myeloma. And we believe this is only the beginning. This approval validates years of scientific research and strengthens our confidence in the potential of this approach as we continue to advance our innovative pipeline on behalf of patients with significant unmet needs.”

Approval of ZENBEXUS is based on results from the Phase 3 EXCALIBER-RRMM trial evaluating ZENBEXUS, daratumumab and hyaluronidase-fihj and dexamethasone (ZDd; n=207) compared to daratumumab, bortezomib and dexamethasone (DVd; n=213) in patients with RRMM.1 At a median follow-up of 16 months, results showed treatment with ZDd demonstrated a statistically significant improvement in one of the dual primary endpoints of minimal residual disease (MRD)-negative complete response (CR) in 41% of patients (n=85; 95% CI: 34-48) vs. 21% of patients (n=44; 95% CI: 15-27) treated with DVd (p < 0.0001).1 MRD-negativity is among the deepest measures of response in multiple myeloma and is considered predictive of improved progression-free survival (PFS).2 This FDA decision marks the first approval in relapsed or refractory multiple myeloma based on MRD-negative CR.

“The FDA approval of iberdomide marks the anticipated arrival of a new therapeutic class for relapsed or refractory multiple myeloma and has the potential to make a meaningful difference for patients,” said Sagar Lonial, MD, FACP, FASCO, EXCALIBER-RRMM lead investigator and chief medical officer of the Winship Cancer Institute of Emory University. “The strong results observed with the CELMoD-based combination within a familiar triplet approach creates the potential for a new treatment foundation in multiple myeloma.”

The combination of ZDd was observed to have a safety profile that is expected of the combination, with 7.8% of patients discontinuing ZDd due to adverse reactions.1 Among the key safety findings, ZDd can cause serious, life-threatening, or fatal infections and severe neutropenia.1 Neutropenia and infections in patients who received ZDd occurred at a rate of 90.2% and 78.9%, respectively, leading to few discontinuations (1% and 1.5%, respectively).1 The most common adverse reactions (≥20%) in the ZDd arm and DVd arm, respectively, were upper respiratory tract infection (54% and 52%), fatigue (36% and 33%), musculoskeletal pain (35% and 33%), pneumonia (34% and 17%), diarrhea (33% and 36%), motor dysfunction (26% and 17%), rash (26% and 15%), sleep disorder (25% and 28%), hypogammaglobulinemia (24% and 12%), COVID-19 (23% and 16%), and constipation (20% and 22%).1 Serious adverse reactions in ≥2% of patients included pneumonia (26%), upper respiratory tract infection (6.4%), second primary malignancy (5.9%), neutropenia (4.9%), febrile neutropenia (3.9%), COVID-19 (4.4%), and sepsis (2.9%).1 Fatal adverse reactions occurred in 10 patients (4.9%) who received ZENBEXUS.1 Sepsis (1.5%) was the only fatal drug reaction that occurred in more than 1 patient.1 The following fatal adverse reactions occurred in 1 patient each: listeria encephalitis, influenza, lung adenocarcinoma, cardiac arrest, large intestine perforation, metabolic acidosis, and respiratory failure.1

“The goal for every person living with multiple myeloma is not simply to live longer, but to live well,” said Heather Cooper Ortner, president and chief executive officer of the International Myeloma Foundation. “That is why it is important to have access to effective therapeutic options, particularly in the community setting where the majority of myeloma care is delivered. This approval represents an important step forward by expanding treatment options for patients facing their first relapse. Every new option gives patients and their healthcare teams additional choices as treatment needs evolve, as well as renewed hope for the future.”

ZENBEXUS was granted Breakthrough Therapy designation and accelerated approval based on MRD-negative CR at any time in the EXCALIBER-RRMM study.1 This review was conducted under the FDA’s Project Orbis initiative, which enables concurrent review by the health authorities in several other countries.

While ZENBEXUS is the first FDA approved CELMoD therapy, a New Drug Application for mezigdomide, an investigational CELMoD, in combination with carfilzomib and dexamethasone is also currently under review with the FDA with a Prescription Drug User Fee Act target date of May 13, 2027.

Bristol Myers Squibb offers various programs and resources to address the needs of patients and caregivers, and provides support that allows for access to therapies, including ZENBEXUS.

About EXCALIBER-RRMM
EXCALIBER-RRMM (NCT04975997) is a Phase 3, multicenter, two-stage, randomized, open-label study evaluating the efficacy and safety of ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma (RRMM).2 The study included a dose optimization stage and was designed to assess dual-primary endpoints of minimal residual disease (MRD) negativity and progression-free survival (PFS), with additional secondary endpoints including overall survival (OS), overall response rate (ORR), safety and sustained MRD negativity.2 The study remains ongoing to assess the primary endpoint of PFS. Eligible participants included adults with 1 to 2 prior lines of anti-myeloma therapy and progressive disease.2 A total of 939 patients were randomized.1 The primary efficacy population for MRD negativity included the first 420 patients randomized to the ZENBEXUS (1 mg) + Dd arm (n=207) or the comparator daratumumab, bortezomib, and dexamethasone (DVd) arm (n=213).1 Treatment in both arms was administered until disease progression or unacceptable toxicity.1

This approval, the first in RRMM based on MRD-negative complete response (CR), marks the first public disclosure of MRD-negative CR data from the EXCALIBER-RRMM trial. The MRD data were first disclosed at the time of approval to preserve the integrity of the study while additional endpoints mature. The study remains ongoing, with patients continuing to be evaluated for PFS, one of the trial's dual primary endpoints. Full data from EXCALIBER-RRMM are expected this year.

About Minimal Residual Disease (MRD)
Minimal residual disease (MRD) refers to the small number of cancer cells that may remain in a patient’s body after treatment and are undetectable using conventional diagnostic methods.3 In multiple myeloma, MRD assessment has emerged as a highly sensitive and clinically meaningful tool for evaluating treatment response.3 MRD negativity does not necessarily mean all cancer cells are gone.3

Modern MRD detection methods, such as next-generation sequencing (NGS) and next-generation flow cytometry (NGF), can identify one malignant cell among 100,000 (threshold for MRD) to 1,000,000 normal cells, offering unprecedented precision in measuring disease burden.3 MRD is increasingly being used in clinical trials as a surrogate endpoint for progression-free survival (PFS) and is gaining recognition from regulatory authorities for its role in accelerating approval timelines.2

Indication
ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Based on the mechanism of action and findings in animal studies, ZENBEXUS can cause birth defects or embryo-fetal death in humans. ZENBEXUS is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.

WARNINGS AND PRECAUTIONS

Embryo-Fetal Toxicity

Females of Reproductive Potential: Must avoid pregnancy while taking ZENBEXUS and for at least 4 weeks after completing therapy. Advise females of reproductive potential of the potential risk to a fetus and to use 2 methods of effective contraception for at least 4 weeks before beginning ZENBEXUS therapy, during therapy, during dose interruptions and for at least 4 weeks after the last dose of ZENBEXUS therapy. Refer patients who can become pregnant to a qualified provider of contraceptive methods, if needed.

Two negative pregnancy tests with a sensitivity of at least 25 mIU/mL must be obtained prior to initiating therapy. Pregnancy testing should be performed weekly during the first 4 weeks of treatment. Thereafter, testing should occur every 4 weeks in patients with regular menstrual cycles, or every 2 weeks in patients with irregular menstrual cycles.

Females of reproductive potential taking ZENBEXUS must not donate eggs during treatment and for 4 weeks after completion.

Males: ZENBEXUS may pass into human semen. Advise patients who can impregnate partners to use effective contraception during treatment and for 4 weeks following the discontinuation of ZENBEXUS therapy. Male patients taking ZENBEXUS must not donate sperm during treatment and for 4 weeks after completion.

Blood Donation: Patients must not donate blood during treatment with ZENBEXUS and for 4 weeks following discontinuation of ZENBEXUS therapy.

ZENBEXUS REMS

ZENBEXUS is available only through a restricted program called ZENBEXUS REMS, because of the risk of embryo-fetal toxicity. Prescribers must be certified with and patients must be enrolled in the ZENBEXUS REMS Program and comply with ongoing monitoring and contraception requirements. Further information about ZENBEXUS REMS, including information for pharmacies, wholesalers, and distributors, is available at www.ZENBEXUSREMS.com or by telephone at 1-888-423-5436.

Serious Venous and Arterial Thromboembolism

ZENBEXUS can cause serious and life-threatening venous thromboembolic events (DVT and PE) and arterial thromboembolic events (myocardial infarction and stroke). In the EXCALIBER-RRMM study (N=204), venous thromboembolic events occurred in 6.4% of patients treated with ZENBEXUS combined with daratumumab and hyaluronidase-fihj and dexamethasone (IberDd) despite mandatory thromboembolism prophylaxis. The incidence of DVT was 3.4% and the incidence of PE was 1.5%.

Arterial thromboembolic events occurred in 3.4% of patients. The incidence of myocardial infarction was 2.0%, and the incidence of stroke (CVA) was 1.5%.

Monitor patients for signs and symptoms of thromboembolic events during treatment with ZENBEXUS. Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors. In patients who develop a thromboembolism, interrupt ZENBEXUS and initiate anticoagulant therapy according to guidelines.

Neutropenia

ZENBEXUS can cause severe neutropenia. In the EXCALIBER-RRMM study, all-grade neutropenia was reported in 90.2%, Grade 3 in 30.9%, and Grade 4 in 53.4% of patients in the IberDd arm. Febrile neutropenia occurred in 5.4% of patients.

Monitor complete blood count throughout treatment with ZENBEXUS. Interrupt, reduce dosage, or discontinue ZENBEXUS, as necessary. Initiate granulocyte colony-stimulating factor (GCSF) as appropriate per guidelines.

Infections

ZENBEXUS can cause serious infections, including life-threatening or fatal infections. Patients with active or uncontrolled infection should not start ZENBEXUS treatment until the infection is controlled. In the EXCALIBER-RRMM study, infections, including opportunistic infections, were reported in 78.9%, Grade 3 in 35.8%, Grade 4 in 3.4%, and fatal infections in 2% of patients receiving IberDd. Serious infections occurred in 40% of patients. Discontinuations due to infections occurred in 1.5% of patients.

Monitor patients for signs and symptoms of infection prior to and during treatment with ZENBEXUS and treat appropriately. Withhold or reduce the dose based on severity.

Consider prophylactic anti-infective medications according to current practice guidelines.

Second Primary Malignancies

In the EXCALIBER-RRMM study, at a median follow-up time of 16 months, second primary malignancies (SPM) occurred in 6.9% of patients in the IberDd arm and 4.9% of patients in the daratumumab and hyaluronidase-fihj, bortezomib, and dexamethasone (DVd) arm.

Monitor patients for the development of SPM.

ADVERSE REACTIONS

Serious adverse reactions occurred in 58.3% of patients receiving ZENBEXUS. Serious adverse reactions in ≥2% of patients included pneumonia (26%), upper respiratory tract infection (6.4%), SPM (5.9%), neutropenia (4.9%), febrile neutropenia (3.9%), COVID-19 (4.4%), and sepsis (2.9%). Fatal adverse reactions occurred in 10 patients (4.9%) who received ZENBEXUS. Sepsis (1.5%) was the only fatal drug reaction that occurred in more than 1 patient. The following fatal adverse reactions occurred in 1 patient each: listeria encephalitis, influenza, lung adenocarcinoma, cardiac arrest, large intestine perforation, metabolic acidosis, and respiratory failure.

The most common adverse reactions (≥20%) in the IberDd arm and DVd arm, respectively, were upper respiratory tract infection (54% and 52%), fatigue (36% and 33%), musculoskeletal pain (35% and 33%), pneumonia (34% and 17%), diarrhea (33% and 36%), motor dysfunction (26% and 17%), rash (26% and 15%), sleep disorder (25% and 28%), hypogammaglobulinemia (24% and 12%), COVID-19 (23% and 16%), and constipation (20% and 22%).

The most common Grade 3 to 4 laboratory abnormalities (≥30%) in the IberDd arm and DVd arm, respectively, were neutropenia (77% and 11%), leukopenia (69% and 18%), and lymphopenia (62% and 51%).

DRUG INTERACTIONS

Effects of Other Drugs on ZENBEXUS

Strong or Moderate CYP3A Inhibitors: Coadministration of ZENBEXUS with strong or moderate CYP3A inhibitors should be avoided. If a strong or moderate CYP3A inhibitor must be used in combination with ZENBEXUS, reduce the ZENBEXUS dose. Concomitant use with strong or moderate CYP3A inhibitors may increase the risk of adverse reactions.

Strong or Moderate CYP3A Inducers: Coadministration of ZENBEXUS with strong or moderate CYP3A inducers should be avoided. Concomitant use with a strong or moderate CYP3A inducer may decrease the efficacy of ZENBEXUS.

SPECIFIC POPULATIONS

Pregnancy (See the BOXED WARNINGS)

There is a pregnancy exposure registry that monitors outcomes in patients exposed to ZENBEXUS during pregnancy. See the ZENBEXUS REMS WARNINGS AND PRECAUTIONS section.

Lactation

Advise women not to breastfeed during treatment with ZENBEXUS. Refer to the Prescribing Information for daratumumab hyaluronidase-fihj or dexamethasone for additional information.

Females and Males of Reproductive Potential

ZENBEXUS can cause fetal harm when administered during pregnancy.

Pregnancy Testing, Females of Reproductive Potential, and Males: See the Embryo-Fetal Toxicity WARNINGS AND PRECAUTIONS section.

Geriatric Use

In patients treated with IberDd, the incidence of serious adverse reactions was 53%, 56%, and 74% in adult patients younger than 65 years of age, 65 years of age to younger than 75 years of age, and 75 years of age and older, respectively.

Renal Impairment

Reduce the ZENBEXUS dose in patients with estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 not on dialysis. If dose modification is needed due to adverse events, reduce the ZENBEXUS dose to 1 mg every other day on Days 1 to 21 of a 28-day cycle.

Please see full Prescribing Information for ZENBEXUS including Boxed WARNINGS.

About Targeted Protein Degradation and CELMoD
Targeted protein degradation (TPD) is a differentiated research platform at Bristol Myers Squibb built on more than two decades of scientific expertise, providing new avenues to degrade therapeutically relevant proteins that were previously considered difficult to address. BMS is the only company that has successfully developed and commercialized protein degrader agents for the treatment of multiple myeloma. These agents, known as immunomodulatory drugs (IMiDs), helped establish the current standard of care in the treatment of this disease, which remains without a cure. BMS is building on this foundation with several investigational protein degraders in clinical trials, leveraging three different modalities including cereblon E3 ligase modulators (CELMoDs), ligand-directed degraders (LDDs), and degrader antibody conjugates (DACs). This three-pronged approach enables matching the right therapeutic modality to a molecular mechanism of action to modulate targets most effectively and ultimately provides more opportunities for potential breakthroughs that may offer meaningful new options for patients across a broad range of diseases, in and beyond hematology and oncology. Learn more about the science behind TPD at Bristol Myers Squibb here.

About Ongoing Trials
ZENBEXUS™ is also being evaluated in the EXCALIBER Maintenance study.

About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X, YouTube, Facebook and Instagram.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, whether ZENBEXUS™(iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the indication described in this release will be commercially successful, any marketing approvals, if granted, may have significant limitations on their use, and, that continued approval of ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) described in this release may be contingent upon verification of progression-free survival, the dual primary endpoint of the EXCALIBER-RRMM trial and potential further verification and description of clinical benefit in confirmatory trials. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporatefinancial-news

References

ZENBEXUS Prescribing Information. ZENBEXUS U.S. Product Information. August 2026. Princeton, N.J.: Bristol Myers Squibb Company. Lonial S, Dimopoulos MA, Berdeja JG, et al. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025;21(14):1761-1769. doi:10.1080/14796694.2025.2501920 Szalat RE, Anderson KC, Munshi NC. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024;109(7):2049-2059. doi:10.3324/haematol.2023.284662.

3 Battery Stocks to Buy and Hold for the Rest of the DecadeEnerSys NYSE: ENS reported record first-quarter fiscal 2027 results, with sales rising 5% from a year earlier to $936 million as favorable price mix, higher volumes and foreign-currency translation supported growth. The company said its Network & Infrastructure Solutions and Precision Power Solutions businesses performed strongly, while Industrial Mobility Solutions continued to face weaker material-handling demand despite an early recovery in transportation.

President and CEO Shawn O'Connell said the quarter reflected strength in data centers, communications and defense markets, along with operating-expense discipline and stock repurchases supported by cash generation. First-quarter orders rose 7% year over year, while book-to-bill was 1.06 times. Backlog was relatively flat from the prior year and increased 2% sequentially.

Get Enersys alerts:

Profitability Boosted by Tariff Refunds and Tax Credits
Chief Financial Officer Andi Funk said the quarter included a $31 million, or $0.63-per-share, one-time benefit from refunds of previously paid IEEPA tariffs. The refunds were not included in the company’s guidance or its operational segment results.

Gross profit increased 24% year over year to $313 million, and gross margin expanded 510 basis points to 33.5%. Excluding the tariff refunds, gross profit rose 12% and gross margin improved 180 basis points. The company also received $9 million in expanded 45X manufacturing tax-credit benefits, largely related to moving production from its Monterrey, Mexico, plant to its Richmond, Kentucky, facility.

Adjusted operating earnings rose 47% from the prior-year period, while adjusted EBITDA increased 50% and adjusted diluted earnings per share climbed 65%. Excluding tariff refunds, adjusted operating earnings increased 22% with 45X benefits and 21% without them, according to the company.

EnerSys also changed its adjusted-metric presentation beginning this quarter to exclude non-cash stock-based compensation expense from adjusted operating earnings, adjusted EBITDA and adjusted diluted EPS. Prior-year figures were recast for comparability.

Segment Results Highlight Data Centers and Defense

Network & Infrastructure Solutions: Revenue increased 9% to $428 million, while adjusted operating earnings rose 50% to $45 million. Adjusted operating margin improved 280 basis points to 10.5%. The company cited demand for power electronics, data-center products and service offerings.
Industrial Mobility Solutions: Revenue declined 3% to $407 million, and adjusted operating earnings fell 11% to $38 million. The segment’s 9.3% adjusted operating margin was down 70 basis points, as lower material-handling volumes offset price mix and cost improvements.
Precision Power Solutions: Revenue grew 24% to $101 million, with adjusted operating earnings increasing 48% to $18 million. Adjusted operating margin rose 280 basis points to 18.2%, driven by aerospace and defense demand, particularly for counter-drone and missile-defense applications.

O'Connell said data-center revenue grew in the low teens during the quarter, while data-center orders increased more than 80% from a year earlier. Funk noted that such orders can extend 12 to 36 months, providing visibility into demand for the company’s lead-based offerings.

The company expects its recently launched DataSafe Noir lithium offering for data centers to begin contributing meaningfully to revenue in fiscal 2028. O'Connell said the product has generated customer interest due to its energy density, cost competitiveness and the ability to pair it with EnerSys’ service network.

In Industrial Mobility, management said transportation orders nearly doubled year over year in the first quarter, while material-handling orders declined by a high-single-digit percentage. EnerSys expects material-handling demand to improve later in fiscal 2027 and said it plans to begin recognizing revenue from its next-generation lithium offering in the second half.

DOE-Supported Lithium Plant Planned in South Carolina
EnerSys finalized a U.S. Department of Energy grant for a planned lithium-cell manufacturing facility in Greenville, South Carolina. The facility will focus on defense applications and serve as a Lithium and Advanced Technologies Center of Excellence.

The plant is expected to have initial annual production capacity of approximately 1 gigawatt-hour and will manufacture high-energy-density cells for manned platforms, soldier power, space and autonomous systems. O'Connell said the facility is designed for specialized defense applications requiring smaller-format cells, specialized equipment and security protocols rather than broad commercial lithium production.

The revised DOE grant will provide approximately $150 million toward the project’s estimated $650 million cost. EnerSys expects its approximately $500 million net investment to be funded entirely through operating cash flow. The company also cited an approximately $200 million state and local incentive package from South Carolina and Greenville County.

Construction is planned to begin in the first half of fiscal 2028, with full production expected about three years after construction begins. Management expects the investment to generate an internal return in the mid-20% range.

Cash Flow, Capital Returns and Outlook
Operating cash flow was $230 million and capital expenditures totaled $12 million, producing $218 million in free cash flow compared with negative $32 million a year earlier. The result was aided by a $115 million U.S. federal tax refund and tariff-refund receipts. As of July 5, EnerSys held $531 million in cash and cash equivalents, while net debt totaled $522 million.

During the quarter, the company repurchased 219,000 shares for $50 million at an average price of about $229 per share. It had nearly $900 million remaining under its repurchase authorization. The board also increased the quarterly dividend 10% to $0.2875 per share for the second quarter of fiscal 2027.

For the fiscal second quarter, EnerSys forecast net sales of $955 million to $995 million and adjusted diluted EPS of $3.15 to $3.25, including $42 million to $47 million of 45X benefits to cost of sales. Excluding 45X benefits, it expects adjusted diluted EPS of $1.95 to $2.05, representing growth of about 25% at the midpoint from the prior-year period.

About Enersys (NYSE:ENS)Enersys, headquartered in Reading, Pennsylvania, is a global leader in stored energy solutions, specializing in manufacturing and distributing industrial batteries, battery chargers, power equipment, and related accessories. The company serves a diverse range of end markets, including telecommunications, data centers, medical, aerospace, defense, electric vehicle motive power, and utility outcomes. Its products are engineered to deliver critical reserve power and motive power applications across key infrastructure and industrial sectors.

The company's product portfolio encompasses lead-acid batteries, lithium-ion energy storage systems, chargers, inverters, power management software, and a broad array of battery accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Enersys Right Now?Before you consider Enersys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enersys wasn't on the list.

While Enersys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Key Takeaways:

Parsons was awarded a $70 million task order under the U.S. Air Force's Air Base Air Defense (ABAD) contract to provide integration, testing, deployment, maintenance, and operational transition support for U.S. Air Forces in the Europe-Air Forces Africa (USAFE-AFAFRICA) region.The company will provide integration, testing, deployment, maintenance, and operational transition of Point Defense capabilities. CHANTILLY, Va., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that it has been awarded a $70 million ceiling task order under the U.S. Air Force's Air Base Air Defense (ABAD) contract to provide integration, testing, deployment, maintenance, and operational transition support for operational capabilities throughout the USAFE-AFAFRICA region. The task order has a four-year period of performance with three 12-month option periods and expands upon Parsons' ongoing support of the Air Force's ABAD mission.

"Parsons is honored to continue supporting the U.S. Air Force's critical force protection mission across Europe and Africa," said Mike Kushin, president of Parsons' Defense and Intelligence business. "This award reflects our proven ability to integrate and operationalize exquisite defense capabilities in complex, fluid environments. By expanding our role on the ABAD program, we will help strengthen the readiness, resilience, and protection of U.S. and allied forces throughout the USAFE-AFAFRICA theater."

Under the task order, Parsons will support the integration, testing, fielding, sustainment, maintenance, and operational transition of point defense systems designed to defend personnel, aircraft, installations, and other critical assets from emerging aerial threats – including counter unmanned aircraft systems (CUAS).

As the threat environment continues to evolve, the need for scalable and integrated air base defense solutions remains critical to enabling freedom of maneuver and mission success across contested and dynamic operational environments.

This award builds upon Parsons' established performance supporting the ABAD program and reinforces the company's position as a trusted partner delivering advanced defense technologies and mission-focused solutions to the U.S. Department of War.

Parsons brings decades of experience in air and missile defense, systems engineering, mission integration, operational support, and rapid capability deployment. The company continues to help customers address increasingly complex national security challenges through innovative, mission-ready solutions that enhance operational effectiveness and improve resilience across the all-domain battlespace.

To learn more about Parsons' integrated missile defense capabilities, visit www.parsons.com/missile-defense-c5isr/.

About Parsons:

Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Media Contact:                                        
Bernadette Miller
+1 980.253.9781
[email protected]

Investor Relations Contact:
Dave Spille
+1 703.775.6191
[email protected]

Ciena Stock: Powering the AI Boom - A Network Infrastructure PlayExtreme Networks NASDAQ: EXTR is positioning its Wi-Fi 7 products, network automation software and expanding data center capabilities to benefit from an enterprise networking upgrade cycle tied to artificial intelligence, higher-bandwidth applications and security needs, according to Stan Kovler, the company’s senior vice president of corporate development and investor relations.

Speaking at an Oppenheimer event, Kovler said customers are increasingly moving to next-generation networking technology, including Wi-Fi 7, which offers greater bandwidth, reliability and more predictable connectivity. He said some customers are upgrading directly from Wi-Fi 4 or Wi-Fi 5 rather than moving through Wi-Fi 6 or Wi-Fi 6E.

Get Extreme Networks alerts:

Wi-Fi 7 Demand Driven by Venues, Video and Connected Systems
Arista Networks Advances the Era of AI and Microperimeters Kovler highlighted large venues as a key use case for higher-capacity wireless networks. Stadium operators are deploying thousands of Wi-Fi access points to support growing concurrent usage, including live streaming, video sharing, digital concessions and security applications.

“Now pretty much everyone is on Wi-Fi at a lot of these events,” Kovler said, citing the need to support users at venues such as large college football stadiums. He said Wi-Fi remains less expensive to deploy than 5G in many venue environments, estimating that Wi-Fi can be three to four times cheaper to deploy than a cell-site-based alternative.

Extreme Networks Snags an Upgrade on Inventory NormalizationThe company is also seeing networking demand expand into locations and applications that historically had less connectivity, including manufacturing facilities, retail checkout systems and airport passenger-processing systems. Kovler pointed to facial recognition, 4K video, factory automation and connected devices as examples of workloads requiring more network capacity and upgraded switching infrastructure.

Security is another driver, particularly in manufacturing and regulated industries. Kovler said Extreme’s fabric technology can create separate virtual networks for individual production lines, potentially helping contain a cyberattack within a limited area rather than allowing it to spread across an organization.

He also cited demand for sovereign-cloud-style deployments, in which government and regulated-industry customers operate management systems in protected environments instead of relying on public cloud infrastructure.

Platform ONE Expands AI Automation Features
Extreme Networks plans to roll out an upgrade to its Extreme Platform ONE software later in the month, Kovler said. The company calls the next-generation capability “Agent ONE,” which is intended to expand the use of AI in network administration.

According to Kovler, the platform initially focused on knowledge-based searches and helping network engineers find information. Future capabilities are expected to provide greater automation, including a “Coworker mode” that can schedule tasks and automate processes. A subsequent offering planned for introduction in October, called “Operator mode,” is designed to address agent-to-agent workflows and more autonomous network operations.

Kovler said the primary near-term productivity benefit should be faster troubleshooting and reduced mean time to resolution. AI can analyze logs and network events in an automated way, potentially allowing IT teams to identify and resolve issues more quickly than through manual processes, he said.

He characterized the economic benefit primarily as cost avoidance rather than immediate workforce reductions. As organizations and their networks grow, automated management tools could reduce the need to add personnel, he said.

Subscription Transition and Data Center Investment
Kovler said Extreme Platform ONE bundles support with AI-driven subscription management capabilities. The bundle represented 30% of the company’s subscription bookings in fiscal 2026 and reached 50% of subscription bookings in the fourth quarter, according to his remarks.

Extreme is transitioning customers from a discrete support model toward a SaaS-oriented subscription model. Kovler said subscriptions accounted for 57% of deferred revenue in the latest quarter. The company aims to move roughly half of its customer base to Extreme Platform ONE by the end of fiscal 2027, compared with approximately 10% at the end of fiscal 2026, and expects to largely complete the transition by fiscal 2028.

He said fiscal 2027 will be a transition year, as the bundling of product lines affects the discrete support revenue line. However, he expects SaaS annual recurring revenue to reaccelerate as subscription revenue is recognized from deferred revenue, with an inflection anticipated toward the end of the fiscal year.

The company is also investing in data center offerings supporting speeds of 400 and 800, Kovler said. He expects enterprises to invest more in on-premises compute and AI workloads over time. Extreme aims to use Platform ONE as a common management layer for both campus networks and future data center switches.

Pricing, Supply and Market-Share Opportunity
Kovler said Extreme expects another year of double-digit product revenue growth and believes it can gain share from larger incumbents. He said aging customer equipment, end-of-life products and competitor product-line transitions may create opportunities, particularly in government and regulated markets where contracts can be reopened for bidding.

The company has raised prices twice during the past year, while some competitors have raised prices more frequently, Kovler said. Extreme is guaranteeing pricing for customers that register interest and deals through October and November, a strategy he said is intended to support orderly purchasing and supply-chain planning rather than encourage a short-term buying surge.

He added that the company has secured memory supply and has visibility into its memory pricing for the year. In certain product lines, he said, competitors are facing longer lead times, which Extreme believes can support additional share gains.

Kovler described current backlog as improving but remaining at “very reasonable levels,” rather than reaching the elevated levels seen during the prior supply-chain-driven cycle. He said the company prefers measured demand growth and is seeking to avoid customers placing orders far in advance of actual delivery needs.

About Extreme Networks (NASDAQ:EXTR)Extreme Networks, Inc NASDAQ: EXTR is a global provider of end-to-end networking solutions designed to support enterprise, data center, and service provider environments. The company's product portfolio encompasses high-performance wired and wireless access switches, routers, network security appliances, and software-defined networking (SDN) tools. Driven by a cloud-native management architecture, Extreme's Intelligent Edge Platform integrates network analytics, automation and orchestration capabilities to help organizations optimize performance, reduce operational complexity and strengthen security.

Since its founding in the mid-1990s and subsequent public listing in 1999, Extreme Networks has expanded its technology footprint through targeted acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Extreme Networks Right Now?Before you consider Extreme Networks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extreme Networks wasn't on the list.

While Extreme Networks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

EDEN PRAIRIE, Minn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Winnebago Industries, Inc. (NYSE: WGO), a leading outdoor recreation product manufacturer, today announced strategic actions to optimize its manufacturing footprint, enhance operational efficiency and position its premium brands for long-term growth.

As part of an ongoing enterprise initiative to align operations with market demand and maximize the use of existing resources, Winnebago Industries is making targeted manufacturing adjustments across two of its RV brands. The Winnebago brand's towable RV production operations will relocate to the nearby production campus where Grand Design RV products are currently manufactured in Middlebury, Indiana, providing access to a modern manufacturing environment and available capacity to support future growth. In addition, the Grand Design RV business will also pursue select line consolidation within its manufacturing footprint.

Separately, the Winnebago motorhome business will relocate production of its B-Van product line from Lake Mills, Iowa, to its primary manufacturing facility in Forest City, Iowa, bringing key manufacturing functions together in a single complex and strengthening coordination across the business. Both the Winnebago Towables campus in Middlebury, Indiana and the Winnebago Motorhome facility in Lake Mills, Iowa, will be closed and offered for sale at a later date.

"Winnebago Industries is focused on building a stronger and more agile enterprise for the future," said Michael Happe, president and chief executive officer of Winnebago Industries. "These actions reflect our commitment to thoughtfully managing our manufacturing footprint, leveraging the strengths of our portfolio and deploying resources where they can create the greatest value. By taking proactive steps today, we are strengthening our ability to serve customers, support dealers and drive long-term growth across our brands."

The company emphasized that Winnebago Towables and Grand Design will remain distinct businesses. Each brand will continue to maintain its own leadership team, product development, sales, dealers and product portfolio. No product lines are being discontinued as a result of these actions.

"One of the advantages of our parent company is the ability to leverage the strengths of each business while preserving what makes every brand unique," said Don Clark, group president of Winnebago Industries' Towables segment and president of Grand Design RV. "These moves allow us to better utilize available capacity while maintaining the culture, customer focus and brand identity that have made Grand Design successful. At the same time, it provides Winnebago Towables with additional resources and a stronger platform for future growth. These brands remain independent, but united in their effort to help more people enjoy their time outdoors."        

"For the Winnebago motorhome business, bringing more of our manufacturing expertise together in Forest City creates a stronger operating foundation and better positions us for the future," said Chris West, president of the Winnebago brand. "By combining talent, production capabilities and key manufacturing functions in one location, we can improve coordination, strengthen execution and continue delivering the quality and innovation our dealers and customers expect."

As these transitions occur over the next several months, dealers and customers can remain confident that business will continue seamlessly. The company does not expect any disruption to production and anticipates no changes to ordering processes, dealer relationships, warranty support, customer service or the ownership experience. Maintaining exceptional service and support for customers and dealers remains a top priority.

About Winnebago Industries

Winnebago Industries, Inc. is a leading North American manufacturer of outdoor recreation products under the Winnebago, Grand Design, Chris-Craft, Newmar and Barletta brands, which are used primarily in leisure travel and outdoor recreation activities. The Company builds high-quality motorhomes, travel trailers, fifth-wheel products, outboard and sterndrive powerboats, pontoons, and commercial community outreach vehicles. Committed to advancing sustainable innovation and leveraging vertical integration in key component areas, Winnebago Industries has multiple facilities in Iowa, Indiana, Minnesota and Florida. The Company’s common stock is listed on the New York Stock Exchange and traded under the symbol WGO. For access to Winnebago Industries' investor relations material or to add your name to an automatic email list for Company news releases, visit http://winnebagoind.com/investors.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Company’s intention to optimize its manufacturing capabilities, benefits of such optimization, and our ability to manage the transitions so that no disruptions occur.  Investors are cautioned that forward-looking statements are inherently uncertain and involve potential risks and uncertainties. A number of factors could cause actual results to differ materially from these statements, including, but not limited to general economic uncertainty in key markets and a worsening of domestic and global economic conditions or low levels of economic growth; ability to innovate and commercialize new products; ability to manage our inventory to meet demand; risk related to cyclicality and seasonality of our business; ability to retain relationships with our suppliers and obtain components; business or production disruptions; inadequate management of dealer inventory levels; increased material and component costs, including availability and price of fuel and other raw materials; exposure to warranty claims and product recalls; ability to retain brand reputation and related exposure to product liability claims. We caution that the foregoing list of important factors is not complete. These forward-looking statements should be considered in light of the discussion of risks and uncertainties described under the heading “Risk Factors” contained in the Company’s most recent annual report on Form 10-K, Quarterly Reports on Form 10-Q, as well as any amendments to such filings, and in other filings with the SEC. The Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this release or to reflect any changes in the Company's expectations after the date of this release or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Media Contact: Daniel Sullivan | [email protected]

Investor Relations Contact: Joan Ondala | [email protected]

 | Source:

ZENTALIS PHARMACEUTICALS

SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities to be sold in the proposed offering will be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of common stock on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from the offering, together with the Company’s existing cash, cash equivalents and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing and the Company’s companion diagnostic in support of its programs, as well as for pre-commercial activities, capital expenditures, working capital and other general corporate purposes.

TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners for the offering.

The securities described above are being offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (SEC) on March 26, 2025, and became effective on April 4, 2025. This offering will be made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.

A preliminary prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement related to the offering and the accompanying prospectus may be obtained, when available, by visiting the SEC’s website or by contacting: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected]; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in this offering in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Zentalis Pharmaceuticals

Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Certain statements contained in this press release, including, without limitation, those relating to the timing, size and completion of the offering, the planned use of proceeds of the offering, the sufficiency of the proceeds of the offering and the Company’s cash, cash equivalents and marketable securities to fund its operating expenses and capital expenditures, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering, the completion of the offering on the anticipated terms or at all, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed offering, the anticipated use of proceeds of the offering, general economic conditions and other risks identified from time to time in the reports the Company files with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and the final prospectus supplement and accompanying prospectus related to the proposed offering to be filed with the SEC, which are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of the statements. The Company’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
[email protected]

Key Takeaways Lamar's Q2 AFFO per share rose 8.1%, while revenues and adjusted EBITDA gained 6.5% and 9%, respectively.Digital revenues rose 15.4%, with digital units up 177 from year-end 2025 and programmatic revenue above 50%.LAMR trades above its five-year median valuation, with $3.5 billion of debt and rate risks.
Lamar Advertising Company (LAMR - Free Report) has entered the second half of 2026 with firmer operating momentum, higher cash generation and an improved full-year outlook. Second-quarter results exceeded expectations, supported by broad demand and faster digital growth.

The question is whether that progress is enough to offset a valuation above Lamar’s five-year norm, sizable debt and continued exposure to advertising cycles and floating-rate financing costs.

Lamar’s Growth Engine Is Gaining StrengthSecond-quarter 2026 adjusted funds from operations (AFFO) per share rose 8.1% year over year to $2.40. Net revenues increased 6.5% to $616.7 million, while adjusted EBITDA advanced 9% to $303.4 million.

Operating cash flow also increased 10% to $252.4 million and free cash flow rose 9.9% to $218.7 million. With results exceeding expectations and bookings for the balance of 2026 pacing well, management raised full-year AFFO per share guidance to $8.75-$8.90.

LAMR’s Digital Mix Supports Further ExpansionLamar ended the quarter with 5,730 digital units, up 177 from year-end 2025. Digital revenues increased 15.4% and represented about one-third of billboard revenues, while programmatic revenues climbed more than 50% and accounted for roughly 10% of digital billboard revenues.

The trend is not isolated to Lamar. OUTFRONT Media Inc. (OUT - Free Report) , another major U.S. out-of-home operator, reported 10% first-quarter 2026 revenue growth across a business spanning billboards, digital displays and transit. Clear Channel Outdoor Holdings, Inc. (CCO - Free Report) posted 8.7% second-quarter 2026 consolidated revenue growth, with digital revenue gains in its America and Airports segments.

Lamar’s Valuation Leaves Less Room for ErrorLAMR trades at 17.58X forward 12-month earnings, above the 16.29X Zacks sub-industry multiple. The stock also stands well above its five-year median of 14.84X, although it remains below its five-year high of 22.85X.

Image Source: Zacks Investment Research

That premium suggests investors are already assigning value to Lamar’s improving growth profile. Continued execution can support the multiple, but weaker bookings, slower digital growth or higher financing costs could make the valuation harder to defend.

LAMR Still Carries Rate and Cyclical RisksLamar had approximately $3.5 billion of total debt as of June 30, 2026. Roughly $1.04 billion, or 29.3% of outstanding long-term debt, carried variable rates, leaving a portion of cash flow exposed to changes in borrowing costs.

Advertising demand also remains sensitive to economic conditions. Management said second-half bookings were about 85-90% of goal, which offers visibility but leaves some revenue dependent on shorter-lead-time demand and advertiser budget decisions.

Lamar’s Income Profile Adds SupportLamar paid $1.60 per share in each of the first two quarters of 2026. Management said it would recommend a third-quarter increase to $1.65 per share, subject to board approval, and expects a regular full-year dividend of at least $6.50 per share.

A year-end special dividend is also likely if current expectations hold. That payout framework adds support for income-focused holders, but it does not remove the risks tied to valuation, economic sensitivity and interest-rate exposure.

LAMR’s Mixed Scores Favor a Measured ViewThe holding case rests on improving operating momentum, expanding digital monetization and stronger cash generation, balanced against a valuation premium and financing risk. Those competing factors argue for patience rather than an aggressive stance.

LAMR currently carries a Zacks Rank #3 (Hold), along with a VGM Score of D. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Its Momentum Score of B is stronger than its Growth Score of C and Value Score of D. The combination supports a measured view: near-term momentum is favorable, but weaker value and broader VGM characteristics temper the case for adding shares at current levels.

 | Source:

Martin Marietta Materials, Inc.

RALEIGH, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”) today announced that its Board of Directors approved an increase in its quarterly cash dividend, raising it from $0.83 per share to $0.84 per share on the Company’s outstanding common stock. This dividend, representing a cash dividend of $3.36 per share on an annualized basis, is payable September 30, 2026, to shareholders of record at the close of business on September 1, 2026.

Ward Nye, Chair, President and Chief Executive Officer, stated, “We are pleased to announce our eleventh consecutive annual dividend increase, reflecting Martin Marietta’s disciplined approach to capital allocation and commitment to delivering attractive long-term returns for shareholders. This dividend increase underscores the durability of our aggregates-led business, the strength of our cash flow generation and our confidence in the Company’s ability to perform through economic cycles. Supported by our proven strategy, leading market positions and enduring demand fundamentals, we remain well positioned to execute our strategic priorities and continue compounding shareholder value.”

Martin Marietta, a member of the S&P 500 Index, is an American-based company and a leading supplier of aggregates and other building materials. Through a network of operations spanning 29 states, Canada and The Bahamas, dedicated Martin Marietta teams supply the resources necessary for building the solid foundations on which our communities thrive. Martin Marietta’s Specialties business provides high-purity magnesia and dolomitic lime products used worldwide in environmental, industrial, agricultural and specialty applications. For more information, visit www.martinmarietta.com or www.magnesiaspecialties.com.

Investor Contact:
Jacklyn Rooker
Vice President, Investor Relations
(919) 510-4736
[email protected]

MLM-D

-

SÃO PAULO--(BUSINESS WIRE)--Nu Holdings Ltd. (NYSE: NU) (“Nu” or the “Company”), the largest digital bank in Latin America, today released its financial results for the second quarter ended June 30, 2026, prepared in accordance with IFRS, as well as complementary managerial results. The financial statements and earnings presentation are available on the Company’s Investor Relations website at www.investors.nu, along with details of the earnings conference call to be held today at 6:00 p.m. Eastern Time / 7:00 p.m. Brasília time.

"Thirteen years ago we started with a simple hypothesis: that a bank built on technology, with no branches and no legacy to defend, could serve hundreds of millions of people better, and at a fraction of the cost. This is no longer a hypothesis, and we are now generating more than a billion dollars in quarterly net income. Earlier this month, we launched our bank in Mexico, becoming the largest digital bank in the country with 16 million customers. That completes our transformation there, unlocking capabilities we did not have before. In Brazil, we are evolving our structure, adding a full banking license to our operations. We also launched Croma for our Super Core customers, taking the same primary banking playbook upmarket into an even larger profit pool. Underpinning all of it, NuFormer, our foundation model for financial behavior, now powers underwriting, customer service, and growth decisions across the company," says David Vélez, founder and global CEO of Nubank.

Q2’26 Results Snapshot
Below are the Q2’26 performance highlights of Nu Holdings Ltd. Unless otherwise noted, all the growth rates presented herein are on an FX neutral basis (FXN)1:

Operating Highlights:

Customer growth - Nu added approximately 4 million customers in Q2'26, reaching a total of 139 million customers globally. In Brazil, Nu reached almost 118 million customers. In Mexico, Nu reached 15.8 million customers (and 16 million as of July, 2026), and in Colombia, Nu surpassed 5 million customers, continuing its steady pace of net additions. Engagement and activity rates - ARPAC reached approximately $17 in Q2'26, growing sequentially quarter-over-quarter (QoQ) once again. Monthly activity rate expanded sequentially to 83.5%, with Brazil surpassing 86% for the first time. Efficiency Ratio - Efficiency Ratio increased to 19.5% in Q2'26 from 17.6% in Q1'26 (21.3% in Q2'25), as real estate and marketing expenses shifted from the first quarter into the second, alongside our continued investments in international expansion. Asset Quality - Leading indicator 15-90 NPL ratio improved 16 bps to 4.8% in Q2'26, with the majority of the improvement coming from seasonality, partially offset by intentional expansions into higher-risk, higher-return segments. Product mix and other minor effects were broadly neutral. 90+ NPLs increased 35 bps to 6.9%, largely reflecting the seasonal migration of first-quarter early delinquencies. Financial Highlights:

Revenue, Net Interest Income (NII) and Risk-adjusted NIM - Nu's Q2'26 gross revenue reached nearly $5.9 billion, up 39% YoY. NII reached $3.7 billion, up 9% QoQ, and Net Interest Margin expanded 180 bps to 22.9%, reflecting portfolio growth, the mix shift toward unsecured lending, and the intentional risk expansions communicated last quarter. Cost of Credit declined 9% QoQ to $1.7 billion, largely reflecting the normal second-quarter improvement in early delinquencies. As a result, Risk-adjusted NIM expanded 290 bps to 12.4%, from 9.5% in Q1'26. Profitability - Gross profit reached $2.4 billion, up 43% YoY and 25% QoQ. Credit's contribution to gross profit rose to 41% as it normalized in line with its expected seasonal pattern, with fees at 25% and float at 34% — all three growing in absolute dollars. Net Income reached $1.1 billion for the first time in Nubank's history, up 17% QoQ and 49% YoY. ROE closed the quarter at 33%. Balance Sheet and Funding - Total credit portfolio expanded 37% YoY and 5% QoQ to $39.4 billion, with credit cards at $26 billion, unsecured lending at $10.3 billion, and secured lending at $3.1 billion. Total deposits reached $45.3 billion, up 18% YoY and 6% QoQ, recovering Q1's seasonal outflows. Brazil closed at $36.4 billion, Mexico at $5.7 billion, and Colombia at $3.3 billion. In Mexico, deposits declined modestly again this quarter as part of a deliberate deposit-optimization strategy, improving cost of funding while maintaining ample liquidity, with Mexico's loan-to-deposit ratio at just 35%. Consolidated cost of deposits held at 88% of interbank rates, 3 p.p. lower than a year ago. Business highlights:

Deepening and Broadening Leadership in Brazil: Nu reached almost 118 million customers in Brazil, with the monthly activity rate surpassing 86% for the first time. Nu already serves most of the Mass Market segment and is the primary bank for a high share of those customers. It is also moving upmarket, where Ultravioleta continues to deepen primary banking relationships in the High Income segment. In July, Nu launched Croma for Super Core customers, offering a dedicated experience, enhanced credit, and broader benefits designed to reward customers for concentrating more of their financial lives with Nu. Beyond consumers, Nu serves more small businesses than any other financial institution in Brazil. Becoming Mexico's Largest Digital Bank: With its August launch, Nu became Mexico's largest digital bank, completing its shift from a credit-first fintech to a full-scale institution. Customer behavior, technology, and regulation are now all moving in the same direction: SPEI transfers below $5 grew more than 60% in the first half, while new central bank rules introduced in June, mandatory for all institutions by year-end, will standardize the payment experience across rails and strengthen network effects. Nu reaches 16.5% of Mexico's adult population, comparable to Brazil in 2020, but cohorts monetize earlier, with ARPAC of $12.3 against $5.6 in Brazil at the same stage. Taken together, these forces create one of the most compelling opportunities Nu has seen in Mexico. Scaling NuFormer and Broadening AI Across the Business: Nu continues to advance NuFormer, its foundation model for financial behavior, building on one of its greatest advantages: over a decade of transaction history across more than 100 million customers. The latest generation quadrupled context length, training speed, and inference speed, while reducing the cost of running models in production. NuFormer is in production across three portfolios — credit cards in Brazil and Mexico, and unsecured lending in Brazil — with SME and Colombian cards now in testing. Beyond underwriting, AI agents handle more than 60% of customer support conversations in Brazil at or above human parity, and Nu is using AI to optimize decisions across credit, deposits, and growth. Credit as a Superpower, Underpinned by Customer Primacy: Nu leads the Brazilian market in Primary Banking Relationships (PBR), and that leadership, combined with the analytical rigor of its underwriting models and the quality of the data those relationships generate, creates a structural credit edge. Credit performance has been steady across every income band, with 90+ delinquency improving in each since July 2025 while the peer bank segments deteriorated, and the widest differentiation in Mass Market and Super Core. Customers with Nu as their PBR show delinquency roughly half the portfolio average, reinforcing that customer primacy is both a growth and a credit advantage. More News From Nu Holdings Ltd.

Back to Newsroom

Why Bloom Energy May Be the Most Important AI Infrastructure StockBrookfield NYSE: BN reported second-quarter distributable earnings before realizations of $1.4 billion, or $0.61 per share, up 15% per share from a year earlier, as growth in asset management and wealth solutions supported results.

Get Brookfield alerts:

Total distributable earnings, including realizations, were $1.5 billion, or $0.66 per share, for the quarter. Over the past 12 months, distributable earnings before realizations totaled $5.7 billion, or $2.39 per share.

Beyond the AI Trade: 3 Defensive Stocks Built for StabilityChief Executive Officer Bruce Flatt said the company raised $98 billion of capital, deployed $100 billion and monetized $40 billion of assets during the first half of 2026. It also completed $130 billion of financings across the franchise.

Flatt said the company sees a constructive environment despite geopolitical conflict, higher energy prices and uncertainty around interest rates. He pointed to rising demand for assets with low obsolescence risk and said digitalization, decarbonization and deglobalization are expanding investment opportunities in artificial intelligence infrastructure, energy, supply-chain reorganization and data sovereignty.

Asset Management fundraising reaches record 3 Stocks to Ride the Manufacturing Sector's Big ComebackBrookfield’s Asset Management business generated distributable earnings of $740 million, or $0.31 per share, during the quarter. The segment raised a record $77 billion of capital, including $17 billion across flagship strategies.

The fundraising total included $7 billion for the seventh vintage of Brookfield’s private equity strategy and $9 billion for the sixth vintage of its infrastructure strategy. President Nick Goodman said both funds are on track to become the largest in their respective series.

Fee-bearing capital increased 19% year over year to $672 billion, while fee-related earnings rose 20%. Goodman said Brookfield expects another record fundraising year.

In July, Brookfield completed the acquisition of Oaktree, bringing the firms fully together and expanding its global credit platform. Flatt said the combined credit business is now among the most comprehensive globally.

The company said its capital base, which includes public-market, institutional, private-wealth, insurance and balance-sheet capital, gives it flexibility to match capital sources with investments across market cycles. Brookfield ended the quarter with $210 billion of deployable capital.

AI and nuclear investment opportunities Management highlighted AI infrastructure as a major opportunity spanning Brookfield’s real estate, energy, infrastructure and credit operations. Flatt said the company is bringing together power generation, transmission, land entitlement, financing and customer relationships to support AI-related development.

Brookfield recently announced a planned $100 billion AI factory project in Kentucky with the U.S. government. Flatt said the U.S. Department of Energy selected Brookfield to repurpose a federally owned industrial site for an AI campus, with the site requiring relatively few additional approvals because of its existing Department of Energy uses.

Goodman said Brookfield expects much of its AI-related activity to be funded through its client funds, co-investments from large institutions and listed affiliates rather than relying primarily on corporate balance-sheet capital. He added that stabilized data-center assets could be recycled to long-duration institutional owners, helping fund further development.

Brookfield also cited Westinghouse as a beneficiary of demand for energy security and nuclear generation. Flatt said the U.S. Department of Energy made a further $17.5 billion financing commitment, alongside utility partners, to acquire long-lead items for reactor construction. Westinghouse has 14 reactors in various stages of construction, line of sight on another 40, and an additional 100 potential projects, according to Flatt.

Wealth Solutions expands with Just Group Wealth Solutions generated distributable earnings of $480 million, or $0.20 per share, up 23% from the prior-year quarter. The business originated $5 billion of annuity sales, while insurance assets rose to more than $190 billion, aided by the acquisition of U.K.-based Just Group, which added $45 billion of insurance assets.

Chief Executive Officer of Wealth Solutions Sachin Shah said Just Group contributed approximately $29 million of earnings during Brookfield’s first full quarter of ownership, representing an initial return on equity of about 12%.

Shah said Brookfield has exited Just’s early-stage direct-to-consumer initiative and is simplifying the business around pension risk transfer and retail annuities. He said Just’s cost structure is two to three times that of some competitors and identified cost reductions and portfolio repositioning as key levers for improving returns.

Brookfield expects its investment origination capabilities in real estate, infrastructure and energy to support higher investment yields for Just’s long-duration pension liabilities. Shah said there is at least 50 basis points of potential spread improvement through cost reductions, with a longer-term path toward a spread closer to 200 basis points.

The company’s North American insurance operations deployed $5 billion into real-asset investments during the quarter, producing an average net investment income yield of 5.7%. Its property-and-casualty business recorded a 99% combined ratio, while the overall gross spread was 2.2%.

Shah said Brookfield sees a path to more than $300 billion of insurance assets by the end of the decade. He also said new bank distribution channels contributed about $200 million of annuity sales in the quarter, and that the company sees potential to add $10 billion to $12 billion of annual sales through bank channels over the next several years.

Operating businesses and capital returns Brookfield’s operating businesses generated $361 million of distributable earnings, or $0.15 per share. Its super-core and core-plus real estate portfolios ended the quarter with occupancy above 95%.

In retail, nearly 1 million square feet of leases commenced at rents 12% above expiring levels. In office, Brookfield signed 4.5 million square feet of leases globally at average net rents 19% above expiring rents.

The company completed several asset sales during the first half, including the initial public offering of Csquare, its U.S. colocation data-center platform, generating about $1.2 billion of proceeds. Brookfield retained a 64% stake. It also sold One Churchill Place in Canary Wharf for £750 million and completed the $650 million sale of construction business Multiplex.

Brookfield realized $121 million of net carried interest during the quarter and ended the period with $12.5 billion of accumulated unrealized carried interest. Goodman said the company expects carry realization to build over time as earlier-vintage infrastructure and Oaktree funds return capital and clear preferred-return thresholds.

The company returned $270 million to shareholders through dividends and share repurchases during the quarter. Year to date, it repurchased approximately $580 million of shares at an average price of $42 per share. The board declared a quarterly dividend of $0.07 per share, payable at the end of September to shareholders of record on Sept. 14, 2026.

About Brookfield (NYSE:BN)Brookfield Corporation NYSE: BN is a global alternative asset manager that specializes in real assets. The company invests in and operates businesses across real estate, infrastructure, renewable power and energy, private equity and credit. Its activities span both ownership and active management of physical assets as well as the operation of investment funds and vehicles that provide institutional and retail investors access to long‑lived, cash‑generating assets.

Brookfield's services include asset management, direct investing, property development and the operation of infrastructure and energy businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Brookfield Right Now?Before you consider Brookfield, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brookfield wasn't on the list.

While Brookfield currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

 | Source:

DLocal Limited

TPV reached nearly US$18 billion (+92% year-over-year), the 7th consecutive quarter of 50%+ growth, and continued acceleration over the last 5 quarters.
Record gross profit: US$127 million (+29% year-over-year).
Operating profit: US$64 million (+15% year-over-year), with Operating Profit/Gross Profit ratio reaching 50% (+6 p.p. quarter-over-quarter); operating leverage to improve in the second half of 2026.
Net income at US$55 million (+28% year-over-year), diluted EPS $0.18 (vs. $0.14 in 1Q26).
Adj. Free Cash Flow US$69 million (+41% year-over-year), Adj. FCF/Net income conversion of 125%.
Guidance update: TPV guidance raised to 60–70% year-over-year and Gross profit to 25–30% year-over-year; Operating profit guidance maintained at 27.5–32.5% year-over-year.

MONTEVIDEO, Uruguay, Aug. 13, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”, “we”, “us”, and “our”) (NASDAQ:DLO), the leading cross-border financial infrastructure platform connecting global merchants to emerging markets, today announced its financial results for the second quarter ended June 30, 2026.

dLocal’s management team will host a conference call and audio webcast on August 13, 2026 at 5:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode.

The live conference call can be accessed via audio webcast at the investor relations section of dLocal’s website, at https://investor.dlocal.com/. An archive of the webcast will be available for a year following the conclusion of the conference call. The investor presentation will also be filed on EDGAR at www.sec.gov.

“TPV growth has remained above 50% year-over-year for seven consecutive quarters, with the last three quarters at or above 70%. Growth has also accelerated over the past five quarters, reaching its highest year-over-year rate in four years. Although the pace and scale of this growth will naturally create more demanding comparisons as we move through the second half of the year and into 2027, what we are seeing today reflects the positive returns on the investments we have made in our platform and portfolio of licenses. It is also a testament to the trust merchants place in us as they build and grow across emerging markets,” said Pedro Arnt, CEO of dLocal.

Second quarter 2026 financial highlights

dLocal reports in US dollars and in accordance with IFRS as issued by the IASB

Total Payment Volume (“TPV”) reached US$17.7 billion in the second quarter of 2026, up 92% year-over-year compared to US$9.2 billion in the second quarter of 2025 and up 26% compared to US$14.1 billion in the first quarter of 2026. In constant currency, TPV growth for the period would have been 80% year-over-year.Revenues amounted to US$399.7 million, up 56% year-over-year compared to US$256.5 million in the second quarter of 2025 and up 19% compared to US$335.9 million in the first quarter of 2026. In constant currency, revenue growth for the period would have been 50% year-over-year. The quarter-over-quarter comparison was driven by volume growth.Gross profit was US$127.2 million in the second quarter of 2026, a new record, up 29% compared to US$98.9 million in the second quarter of 2025 and up 7% compared to US$118.7 million in the first quarter of 2026. In constant currency, gross profit growth for the period would have been 23% year-over-year. The quarterly comparison was driven by (i) Brazil, supported by the ramp-up of ride-hailing and travel merchants alongside sustained e-commerce growth; (ii) Argentina, driven by broad-based growth across e-commerce, ride-hailing and on-demand delivery, as well as lower advancement costs; partially offset by (iii) Mexico, with large Tier 0 merchants hitting higher volume pricing tier along with cost pressure. Underlying volume and revenue growth (64% YoY) remain solid; and (iv) Africa and Asia, with lower contribution from higher FX spread markets (Mozambique and Vietnam) and one-off cost increase in Nigeria.As a result, gross profit margin was 32% in this quarter, compared to 39% in the second quarter of 2025 and 35% in the first quarter of 2026.Gross profit over TPV was at 0.72%, decreasing from 1.07% in the second quarter of 2025 and from 0.84% in the first quarter of 2026, reflecting the higher local-to-local share, the ramp-up of large merchants, and the natural margin dynamics of scaling volume with established merchants and into new payment methods, products, and countries.Operating expenses reached US$63.0 million for the second quarter of 2026, up 46% year-over-year and down 4% quarter-over-quarter. The year- over-year increase reflects the annualization of investments made in the second half of 2025, higher average salaries driven by the annual merit cycle and a limited number of senior strategic hires, and higher marketing spend concentrated in the first half around the World Cup campaign and large merchant events. The sequential decrease partly reflects the absence of the US$4.4 million non-recurring prior-year tax item recorded in OPEX in the first quarter of 2026.As a result, Operating profit was US$64.2 million, up 15% year-over-year and 22% quarter-over- quarter. The Operating Profit to Gross Profit ratio was 50%, up 6 p.p. quarter-over-quarter compared to 44% as reported in the first quarter of 2026 and down 6 p.p. year-over-year compared to 56% as reported in the second quarter of 2025.Net financial result was a US$2.3 million gain, compared to a net finance loss of US$3.8 million in the second quarter of 2025 and a net finance gain of US$5.2 million in the first quarter of 2026.Our effective income tax rate for the period was approximately 16%, in line with the second quarter of 2025 and lower when compared to 26% for the first quarter of 2026, which was elevated by the non-recurring prior-period adjustment, as explained in the previous quarter.Net income for the second quarter of 2026 was US$54.8 million, or US$0.18 per diluted share, up 28% compared to a profit of US$42.8 million, or US$0.14 per diluted share, for the second quarter of 2025, and up 31% compared to a profit of US$41.9 million, or US$0.14 per diluted share, for the first quarter of 2026. The quarterly comparison is explained by higher operational profit and lower tax expenses.Adjusted free cash flow for the second quarter of 2026 amounted to US$68.5 million, up 41% year-over-year compared to US$48.4 million in the second quarter of 2025, and up substantially compared to US$14.7 million in the first quarter of 2026. The improvement reflects the normalization of the temporary working-capital effects (including timing in tax-credit netting and receivables from advancement operations) that had weighed on the first quarter of 2026.As of June 30, 2026, dLocal had US$794.9 million in total cash and cash equivalents, which includes US$369.1 million of Corporate cash and cash equivalents. The Corporate cash and cash equivalents increased by US$115.3 million from US$253.8 million as of June 30, 2025. When compared to the US$451.8 million Corporate cash and cash equivalents position as of March 31, 2026, it decreased by US$82.7 million quarter-over-quarter, explained by the dividends payment and execution of the share repurchase program. Under the $300 million program authorized in March 2026, the Company has repurchased approximately 6.9 million Class A shares for US$86.1 million through the end of the second quarter.Before the date of this release, and following the Board of Directors’ approval of the Company’s financial statements for the second quarter of 2026, ended June 30, 2026, on August 12, 2026 we entered into a credit agreement with certain of our subsidiaries as initial guarantors and the lenders party thereto, providing for a U.S.$150.0 million senior unsecured credit facility. The facility matures on August 14, 2029, and is repayable in 11 equal, quarterly installments of US$13.6 million each, plus interest, commencing six months following the borrowing date, as specified in the Credit Agreement. Interest accrues at Term SOFR (Secured Overnight Financing Rate) plus 2.00% per annum. The proceeds of the facility are intended to be used for general corporate purposes. The following table summarizes our key performance metrics:

 Three months ended on June 30Six months ended on June 30 20262025% change20262025% changeKey Performance metrics(In millions of US$ except for %)TPV17,6949,21292%31,74917,31983%Revenue399.7256.556%735.5473.255%Gross Profit127.298.929%245.8183.834%Gross Profit margin32%39%-7p.p33%39%-5p.pOperating Profit64.255.815%116.9101.615%Operating Profit/Gross Profit50%56%-6p.p48%55%-8p.pNet Income54.842.828%96.789.58%Net Income margin14%17%-3p.p13%19%-6p.p        Adjusted Free Cash Flow reconciliation

We calculate “Adjusted Free Cash Flow” as net cash (used in) / generated from cash flows from operating activities, less (i) changes in working capital (merchant), and (ii) capital expenditures. The working capital (merchant) is defined as (i) changes in Trade receivables net (disclosed in Note 17 to our consolidated financial statements for the period ended June 30, 2026), plus (ii) changes in Trade payables (disclosed in Note 20 to our consolidated financial statements for the period ended June 30, 2026), plus (iii) changes in Other tax liabilities (disclosed in note 21 to our consolidated financial statements for the period ended June 30, 2026). Capital expenditures consist of acquisitions of property, plant and equipment and additions of intangible assets.

Management uses Adjusted Free Cash Flow as a measure for evaluating the Company's cash generation and the cash available for distribution to our shareholders as dividends pursuant to our dividend policy. Adjusted Free Cash Flow is not a financial measure recognized under IFRS and does not purport to be an alternative to cash generated from operating activities or as a measure of liquidity. Our presentation of Adjusted Free Cash Flow has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. See below for a reconciliation of our Adjusted Free Cash Flow to the nearest IFRS measure.

The table below presents a reconciliation of dLocal’s Adjusted Free Cash Flow reconciliation:

$ in thousands (except percentages)Three months ended on June 30Six months ended on June 30 2026202520262025Net cash (used in ) / generated from operating activities140,522124,459233,304219,872Changes in working capital (merchant)¹(62,064)(67,578)(130,455)(115,748)Capital expenditures²(9,910)(8,434)(19,649)(15,946)Adjusted Free Cash Flow68,54848,44783,20088,176      Note: 1 Changes in working capital (merchant) consists of (i) changes in the period in the balance of trade receivables net, plus (ii) changes in the period in the balance of trade payables, plus (iii) changes in the period in the balance of other tax liabilities. 2 Capital expenditures consist of acquisitions of property, plant and equipment and Additions of Intangible Assets.

dLocal Limited
Certain financial information
Consolidated Statements of Comprehensive Income for the three-month and six-month periods ended June 30, 2026 and 2025
(All amounts in thousands of U.S. Dollars except share data or as otherwise indicated)

 Three months ended on June 30Six months ended on June 30 2026202520262025Continuing operations    Revenues399,664256,458735,526473,217Cost of services(272,514)(157,573)(489,692)(289,453)Gross profit127,15098,885245,834183,764     Technology and development expenses(13,298)(7,380)(25,422)(14,147)Sales and marketing expenses(9,892)(4,842)(19,811)(11,977)General and administrative expenses(36,460)(27,003)(79,117)(51,327)Impairment (loss)/gain on financial assets(1,430)(1,415)(2,210)(1,801)Other operating loss(1,909)(2,480)(2,341)(2,902)Operating profit64,16155,765116,933101,610Finance income5,06711,11015,82423,338Finance costs(2,757)(14,895)(8,355)(20,154)Inflation adjustment(1,483)(984)(2,869)(1,869)Other results827(4,769)4,6001,315Profit before income tax64,98850,996121,533102,925Income tax expense(10,213)(8,188)(24,822)(13,450)Profit for the period54,77542,80896,71189,475     Profit attributable to:    Owners of the Group54,63842,81096,61289,440Non-controlling interest137(2)9935Profit for the period54,77542,80896,71189,475     Earnings per share (in USD)    Basic Earnings per share0.190.150.330.31Diluted Earnings per share0.180.140.330.30     Other comprehensive Income    Items that are or may be reclassified to profit or loss:-   Exchange difference on translation on foreign operations1,8054,3034,8527,829Other comprehensive income for the period, net of tax1,8054,3034,8527,829Total comprehensive income for the period56,58047,111101,56397,304     Total comprehensive income for the period is attributable to:Owners of the Group56,52047,010101,46297,184Non-controlling interest60101101120Total comprehensive income for the period56,58047,111101,56397,304      dLocal Limited
Certain financial information
Consolidated Statements of Financial Position as of June 30, 2026 and 2025
(All amounts in thousands of U.S. dollars)

 2026
2025
 on June 30, 2026on June 30, 2025ASSETS  Current Assets  Cash and cash equivalents794,943476,939Financial assets at fair value through profit or loss79,214125,526Trade and other receivables1,149,456487,320Derivative financial instruments169691Other assets25,05529,888Total Current Assets2,048,8371,120,364   Non-Current Assets  Trade and other receivables24,73714,698Deferred tax assets4,1735,961Property, plant and equipment3,8644,208Right-of-use assets2,7524,124Intangible assets94,85068,165Goodwill6,550-Other assets5,7823,792Total Non-Current Assets142,708100,948TOTAL ASSETS2,191,5451,221,312   LIABILITIES  Current Liabilities  Trade and other payables1,554,943691,081Lease liabilities1,1131,201Tax liabilities19,35114,330Derivative financial instruments1,9282,555Financial liabilities64,63256,806Provisions759544Total Current Liabilities1,642,726766,517   Non-Current Liabilities  Deferred tax liabilities6,6763,918Lease liabilities1,6262,696Total Non-Current Liabilities8,3026,615TOTAL LIABILITIES1,651,028773,131   EQUITY  Share Capital576587Share Premium-192,820Treasury Shares-(200,980)Capital Reserve55,45339,241Other Reserves(11,035)(13,190)Retained earnings495,254429,482Total Equity Attributable to owners of the Group540,248447,960Non-controlling interest269220TOTAL EQUITY540,517448,180TOTAL EQUITY AND LIABILITIES2,191,5451,221,312    dLocal Limited
Certain interim financial information.
Consolidated Statements of Cash flows for the the three-month and six-month periods ended June 30, 2026 and 2025
(All amounts in thousands of U.S. dollars)

 Three months ended on June 30Six months ended on June 30 2026
202520262025Cash flows from operating activities    Profit before income tax64,98850,996121,533102,925Adjustments:    Interest Income from financial instruments(5,067)(5,976)(15,657)(11,083)Interest charges for lease liabilities534111082Other interests charges(752)1,5686,7602,452Finance expense related to derivative financial instruments2,9323,1773,6323,591Net exchange differences4699,765(2,147)13,908Fair value loss/(gain) on financial assets at FVPL-(4,791)(167)(12,134)Amortization of Intangible assets7,3285,05514,3909,639Depreciation and disposals of PP&E and right-of-use6084851,2611,188Share-based payment expense, net of forfeitures6,4894,91112,55510,931Other operating gain1,9092,4802,3412,902Net Impairment loss/(gain) on financial assets1,4301,4152,2101,801Inflation adjustment and other financial results2,1873,1805,0509,265 82,57472,306151,871135,467Changes in working capital    Increase in Trade and other receivables(410,436)(13,046)(580,738)8,036Decrease / (Increase) in Other assets(4,265)1,175(18,544)2,200Increase / (Decrease) in Trade and Other payables495,66476,948700,50793,294Increase / (Decrease) in Tax Liabilities(7,261)(2,928)2,316(1,963)Increase / (Decrease) in Provisions298132644Cash (used) / generated from operating activities156,575134,457255,738237,078Income tax paid(16,052)(9,998)(22,434)(17,206)Net cash (used) / generated from operating activities140,522124,459233,304219,872     Cash flows from investing activities    Acquisitions of Property, plant and equipment(241)(515)(763)(1,460)Additions of Intangible assets(9,669)(7,919)(18,886)(14,486)Acquisition of financial assets(65,164)(92,090)(92,040)(133,464)Collections of financial assets83,15386,554111,123133,970Interest collected from financial instruments5,0675,97715,65711,083Cash acquired in a business combination791-791-Payments for investments in other assets at FVPL-(2,500)-(12,500)Net cash (used in) / generated investing activities13,936(10,493)15,882(16,857)     Cash flows from financing activities    Repurchase of shares(75,940)-(86,062)-Share-options exercise paid65940257940Dividends paid(57,211)(149,982)(57,211)(149,982)Interest payments on lease liability(53)(41)(110)(82)Principal payments on lease liability382(478)(366)(1,141)Finance expense paid related to derivative financial instruments601(1,948)(3,300)(5,080)Net proceeds from financial liabilities(47,619)6,224(22,266)12,014Interest payments on financial liabilities5,306(3,835)-(6,001)Other finance expense paid591(1,399)(6,864)(2,113)Net cash used in by financing activities(173,878)(150,520)(175,922)(151,445)Net increase in cash flow(19,419)(36,554)73,26451,570     Cash and cash equivalents at the beginning of the period815,605511,506719,897425,172Net (decrease)/increase in cash flow(19,419)(36,554)73,26451,570Effects of exchange rate changes on inflation and cash and cash equivalents(1,243)1,9871,782197Cash and cash equivalents at the end of the period794,943476,939794,943476,939      About dLocal
dLocal builds financial infrastructure for markets of the future, connecting global enterprises with billions of emerging market consumers in more than 60 countries across high-growth markets in Africa, Asia, the Middle East, and Latin America. Through the "One dLocal" concept (one direct API, one platform, and one contract), global companies can accept payments, send payouts, and settle funds globally without the need to manage multiple local entities and integrations. For more information, visit www.dlocal.com

Forward-looking statements
This presentation may contain forward-looking statements. These forward-looking statements convey dLocal’s current expectations or forecasts of future events, including guidance in respect of total payment volume, gross profit and operating profit. Forward-looking statements regarding dLocal and amounts stated as guidance involve known and unknown risks, uncertainties and other factors that may cause dLocal’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Certain of these risks and uncertainties are described in the “Risk Factors,” and “Cautionary Statement Regarding Forward-Looking Statements” sections of dLocal’s filings with the U.S. Securities and Exchange Commission.

Unless required by law, dLocal undertakes no obligation to publicly update or revise any forward-looking statements to reflect circumstances or events after the date hereof.

Starting in 2026, we provide guidance in respect of Operating Profit, which management believes is useful as a measure to compare our operating results to the operations of other companies in our industry, and to assess our operating performance independently of our capital structure, tax position, and non-cash depreciation and amortization charges.

Investor Relations Contact:
[email protected]

Media Contact:
[email protected]

This press release does not contain sufficient information to constitute an interim financial report as defined in International Accounting Standards 34, “Interim Financial Reporting” nor a financial statement as defined by International Accounting Standards 1 “Presentation of Financial Statements”. The second quarter financial information in this press release has not been audited nor has it been subject to any limited review procedures, whereas the annual results for the year ended December 31, 2025 are audited.

Apple CEO Tim Cook was joined by government officials, including Secretary of Commerce Howard Lutnick, on Thursday to open a new manufacturing facility offering free training and educational classes for businesses in Houston, Texas.

The facility is also where Apple will manufacture Mac Mini desktop computers later this year, the company said. AI servers for Apple are also assembled at a portion of the location.

"We stood up a factory, started production, and shipped the first advanced AI servers off the line, and with Mac Mini production set to begin later this year," Cook said, adding that Apple had spent hundreds of millions of dollars on the facility.

President Donald Trump has for years pressed Apple to make its iPhone in the U.S. While the company has tried to appease the administration, it's also worried that Trump's proposed tariffs could snarl its business.

Apple has chosen to emphasized the things it does build in the U.S., like components, chips, and cover glass. Cook said on Thursday that Apple had sourced more than 20 billion chips from the U.S. last year and 100 million chips from Taiwan Semiconductor Manufacturing Co.'s facility in Arizona.

"For decades, America was the great inventor of the world's technology, and we watched that technology be built everywhere else in the world," Lutnick said at the ribbon cutting. "President Trump said, 'Look, that's got to change.'"

"We needed Apple's commitment to build here in America, because they can uniquely, maybe, lead the charge for advanced manufacturing coming to America," Lutnick continued.

The joint appearance comes in the final weeks of Cook's tenure as CEO of Apple. On Sept. 1, he'll become executive chairman, and longtime Apple hardware executive John Ternus will assume the CEO role.

watch now

Cook's appearance with officials could be an early sign of what his future entails, as Apple said Cook would "assist with certain aspects of the company, including engaging with policymakers around the world."

While Apple has never indicated it would manufacture a U.S. iPhone, the company has said in appearances with the Trump administration that many of its components are made in the U.S., and that it diversified its supply chain away from being entirely in China, making a proportion of U.S.-bound iPhones and Macs in India and Vietnam.

Last August, Apple introduced a $600 billion spending commitment that it called the American Manufacturing Program. Through orders, purchase commitments, and an effort to expand production capacity with several semiconductor companies, Apple said it was supporting U.S. manufacturing. It also opened a manufacturing center offering classes and training in Michigan. Classes at the Houston site will include topics like using machine learning for quality control.

Apple leaders have previously appeared with Trump officials to announce Mac Pro manufacturing and server manufacturing in the U.S., but the Mac Mini is a consumer-facing product with higher sales volumes.

In 2019, Cook appeared with Trump at the Austin, Texas factory where the $6,000 Mac Pro was assembled. Last year, in a White House appearance, Cook said Apple would make servers for Apple Intelligence outside of Houston.

The Mac Mini has never been Apple's most popular PC, but it found a second purpose and sold out in some stores this spring as a free program called OpenClaw gained popularity among artificial intelligence enthusiasts, who found that Apple's smallest and least expensive desktop was perfect for running AI agents.

"When I thought about a Mac Mini, I thought, OK, that's like the computer on your desk," Lutnick said. "And then I see Tim. He goes: 'No, no, no.'"

Lutnick said Cook told him you can run advanced AI models on the computer, "and these things are amazing, right?"

watch now

NEW YORK--(BUSINESS WIRE)--Citi’s U.S. Consumer Cards business today announced that it has entered into an agreement to acquire Kard Financial, Inc. (Kard), a company that operates a commerce media and rewards platform that helps banks and fintechs deepen customer engagement through personalized offers.

With billions of transactions and a network of leading fintechs, banks and neobanks, Kard provides an innovative commerce media platform that connects financial institutions and merchants through verified transaction data and merchant-funded rewards. Its embedded, machine learning-powered personalization and matching capabilities simplify rewards for issuers, deliver meaningful value to customers and help brands reach high-intent consumers with measurable outcomes.

By combining Citi’s scale and payments expertise with Kard’s technology, talent and merchant relationships, the proposed acquisition will strengthen Citi’s commerce ecosystem, enabling more personalized rewards and offers while creating new opportunities to connect customers, merchants and brands.

“We’re focused on helping customers get more value from their everyday spending,” said Abhinav Anand, Citi’s Head of Value Cards, Lending and Commerce. “Kard has built advanced capabilities that complement our vision for the future of commerce and loyalty. With this acquisition, we believe we can work with Kard to accelerate innovation and deliver more personalized experiences for customers while creating new opportunities for brands and merchants to reach, engage and reward consumers in more meaningful ways.”

“Joining forces with Citi marks an exciting new chapter for Kard, our team and our customers,” said Ben Mackinnon, Kard’s Founder and Chief Executive Officer. “I started Kard with the goal of building more rewarding experiences for consumers. Now being able to do that for Citi’s 70 million cardmembers1, on top of the millions we support today, accelerates that original vision towards building the future of commerce.”

Terms of the transaction were not disclosed and are not material to Citi’s financial results. The transaction is subject to satisfaction of customary closing conditions. Until the transaction closes, Citi and Kard will continue to operate as independent organizations. Keefe, Bruyette & Woods, A Stifel Company, acted as exclusive financial advisor to Kard in connection with the transaction. Sullivan & Cromwell LLP acted as counsel to Citi and Latham & Watkins LLP acted as counsel to Kard.

1 As of December 31, 2025. Includes General Purpose and Private Label Credit Cards and Installment Lending, primarily in the U.S.

About Citi
Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.

Additional information may be found at www.citigroup.com | X: @Citi | LinkedIn: www.linkedin.com/company/citi | YouTube: www.youtube.com/citi | Facebook: www.facebook.com/citi

About Kard
Kard is the leading rewards infrastructure powering next-generation personalized rewards through a commerce media network. Using predictive AI and first-party transaction data, Kard helps financial institutions, fintechs, and brands understand and influence real consumer spend. Its flexible, API-driven platform enables partners to deliver personalized, data-driven rewards that deepen engagement, build loyalty, and turn rewards into revenue-generating marketing channels. Kard is backed by leading investors including Underscore Ventures, Fin Capital, and Tiger Global.

Certain statements in this release are “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. These statements are not guarantees of future results or occurrences. Actual results may differ materially from those included in these statements due to a variety of factors. These factors include, among others, satisfaction of the closing conditions to the transaction, including required regulatory approvals; and the precautionary statements included in this release. These factors also consist of those contained in Citi’s filings with the U.S. Securities and Exchange Commission, including, without limitation, the “Risk Factors” section of Citi’s 2025 Form 10-K. Any forward-looking statements made by or on behalf of Citi speak only as to the date they are made, and Citi does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© courtesy of Walmart Inc.

Walmart (NYSE:WMT | WMT Price Prediction) has quietly become one of the most interesting large-cap growth stories in retail, with a digital flywheel that increasingly resembles a diversified commerce platform rather than a traditional big-box operator. After a pullback from winter highs, the risk/reward has tilted back in shareholders’ favor heading into the back half of the year.

Our 24/7 Wall St. price target for Walmart is $128.33, implying 11.75% upside from the current price of $114.84. Our recommendation is buy at a 90% confidence level.

24/7 Wall St. Price Target Summary Metric Value Current Price $114.84 24/7 Wall St. Price Target $128.33 Upside 11.75% Recommendation BUY Confidence Level 90% The Digital Flywheel Is Doing the Heavy Lifting Walmart shares are up 2.07% year to date and 9.89% over the past year, trading roughly 2% below the 52-week high of $135.16 and well off the $94.85 low.

The Q1 FY27 report delivered $175.68 billion in revenue, up 6.1%, with adjusted EPS of $0.66. The standout: global e-commerce sales grew 26% and now represent 23% of net sales, while Walmart Connect advertising rose 44% ex-VIZIO and marketplace sales jumped 50%, the best result in ten quarters.

On the Q2 call, CFO John David Rainey put it plainly: “50% of our incremental profit, excluding claims, was related to advertising, membership, and marketplace.” That is the whole thesis in one sentence.

Why Bulls See a Breakout Ahead The bull case rests on the “two P&L” framework CEO Doug McMillon has highlighted: the traditional store business plus a higher-margin digital layer built on marketplace, advertising, and membership.

TD Cowen carries a $150 price target, arguing the multiple reset offers a favorable entry point. Mizuho sits at $130. The Street consensus is $137.97. If holiday execution matches management’s confidence and Walmart Connect compounds at 40%+, our bull case scenario points to $125.49 by year-end.

What Could Go Wrong Walmart trades at a forward P/E of 38, expensive by historical measure for a business with a 3.07% net margin. Tariff pass-through is hitting inventory costs weekly, and Walmart is absorbing meaningfully. Q1 FCF was negative $1.95 billion on $6.68 billion of capex.

Insider activity is currently net selling. Counterfactual: much of that capex funds automation and fulfillment capacity underpinning the same e-commerce growth bulls are paying for. Under a bear scenario, our model projects $115.83 by December.

How Walmart Compares to Costco and Kroger Costco (NASDAQ:COST) is the obvious membership-model peer. Costco carries a richer forward P/E of 42 and posted 45.5% quarterly earnings growth against 21.5% revenue growth. That premium makes Walmart’s 38 forward multiple look reasonable, particularly given Walmart’s advertising and marketplace optionality Costco lacks.

Kroger (NYSE:KR) is the domestic grocery counterpoint. Kroger’s e-commerce grew 19% last quarter was healthy but visibly slower than Walmart’s 26%. Kroger trades at a mid-teens forward multiple, framing Walmart as the growth-premium name in defensive retail, which supports our target.

Company Forward P/E Recent Rev Growth Walmart 38 6.1% Costco 42 21.5% Kroger ~15 ~5% I’d Buy It Here The 24/7 Wall St. price target of $128.33 reflects a business whose earnings mix is quietly improving even as the top line grows mid-single digits.

I would be a buyer if Q2 confirms e-commerce growth holding above 25% and advertising above 40%. I would step aside if tariff pass-through starts compressing US operating margins in the back half. On balance, this is a buy.

Year 24/7 Wall St. Price Target 2026 $117.88 2027 $128.33 2028 $141.21 2029 $149.49 2030 $161.63 These projections assume Walmart continues executing on digital, advertising, and membership. Significant upside or downside could come from tariff resolution and the pace at which Sparky and agentic commerce scale.

Contact [email protected] for any questions or corrections.

Analyst Samik Chatterjee recently reiterated its Overweight rating on Oracle and assigned a $200 price target, implying more than 30% upside from the stock’s Aug. 12 closing price of $153.28.

More importantly, the bullish call isn’t simply based on faster earnings growth—it rests on the idea that Oracle is evolving into an AI infrastructure company, a transformation that could eventually command a higher valuation multiple.

Oracle’s AI Transformation Is AcceleratingCombined with projected 33% annual revenue growth and approximately 29% annual earnings-per-share growth through fiscal 2030, JPMorgan believes Oracle’s financial profile is changing far more rapidly than its valuation suggests.

In other words, JPMorgan sees Oracle becoming less like a mature software company and more like an AI infrastructure provider with a rapidly expanding cloud business.

Why Investors Remain SkepticalIf Oracle’s growth outlook appears compelling, why does the stock continue to trade at a discount?

According to JPMorgan, the market is fixated on the enormous cost of Oracle’s AI expansion. Building data centers capable of supporting AI workloads requires substantial upfront investment, and the brokerage estimates Oracle could need to raise roughly $20 billion of capital annually, including about $40 billion in fiscal 2027, to support its infrastructure build-out.

Those financing needs have fueled concerns about rising debt levels and the possibility of future equity issuance, weighing on investor sentiment even as Oracle’s AI business continues to expand.

JPMorgan, however, believes investors may be focusing too heavily on those near-term financing risks while underestimating the earnings potential of the infrastructure being built.

A Re-Rating Could Become Oracle’s Biggest CatalystThe brokerage’s central argument is not that Oracle’s capital requirements will disappear. Rather, it believes the market is undervaluing what those investments could produce.

As AI infrastructure becomes a larger share of Oracle’s business, JPMorgan expects the company to maintain healthy operating margins while benefiting from significantly higher revenue and earnings. That combination, the analysts argue, could justify a valuation multiple closer to those enjoyed by AI infrastructure peers rather than traditional enterprise software companies.

For investors, that distinction matters. The upside case for Oracle is no longer simply that cloud revenue will continue growing. It is that the market may eventually stop valuing Oracle as yesterday’s software company and start valuing it as an AI infrastructure leader.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Shares of Micron Technology (MU +4.23%) charged sharply higher on Thursday, jumping as much as 7.3%. As of 2:04 p.m. ET, the stock was still up 6.6%.

The catalyst that sent the semiconductor specialist higher was media reports detailing the company's upcoming capital allocation plans.

Image source: The Motley Fool.

Show me the money In late 2024, Micron received a $6.1 billion chip-making subsidy from the U.S. Department of Commerce to produce semiconductors in the U.S. The agreement, formally known as the CHIPS Incentive Program, rewarded companies that agreed to increase manufacturing in the U.S. One of the stipulations was that none of the funds could be used for share repurchases, and recipients agreed to refrain from stock buybacks for a period of time after receiving the subsidy.

In the fiscal 2026 Q3 earnings call with analysts in June, CFO Mark Murphy revealed that Micron was sitting on what it called "excess cash." He addressed the issue of returning capital to shareholders, saying, "Over time, we expect to return 100% of our excess cash to shareholders."

He went further, noting, "the principal capital return we have will be share repurchase. I said today in the prepared remarks that we intend to increase our capital return from Dec. 9, which is the second anniversary of our CHIPS agreement signature." He pointed to the company's record cash flow, noting that in the past two quarters, Micron had "generated as much as [in] much of the company's history."

Today's Change

(

4.23

%) $

38.54

Current Price

$

949.83

Several press reports have surfaced, recounting that interaction, and the prospect of a robust capital return program has investors cheering.

Even after today's rally, Micron stock is selling for just 22 times earnings, an attractive multiple for a company growing revenue and profits at triple-digit rates. Bears will argue that chip stocks are cyclical and that the current cycle will eventually end. However, as I've detailed before, Micron has taken steps to lock many of its major customers into multi-year, non-cancelable contracts to ensure its windfall continues.

As such, I would argue that Micron stock is still a buy.

Danny Vena, CPA has positions in Micron Technology. The Motley Fool has positions in and recommends Micron Technology. The Motley Fool has a disclosure policy.

The tech sector has been feast or famine at various points this year. It's been strongly affected by the irresistible rise of artificial intelligence (AI). This is the big story in the industry for many investors, and companies at the heart of technology have attracted great interest from the market.

Flush with cash, many have opened their wallets for generous dividend raises of at least 10%. Here's a closer look at three such recent lifts from well-known AI chipmakers -- Nvidia (NVDA +0.54%), Taiwan Semiconductor Manufacturing (TSM +0.31%), and Broadcom (AVGO +0.43%).

Image source: Getty Images.

1. Nvidia Of our trio, Nvidia takes the crown -- and how -- for the highest-percentage dividend raise. It hiked its payout an eye-watering 2,400%!

The big asterisk next to that figure, however, is that Nvidia started from a very low base. With a 10-for-1 stock split in mid-2024, its quarterly distribution was reset at $0.01 per share. It hiked that to $0.25 starting with the June 2026 disbursement.

That's a lot more spend on the shareholder payout, but no one should worry that Nvidia risks financial ruin. (It also added a cool $80 billion to its share repurchase program, adding to the existing $38.5 billion already under authorization.)

These days, its business is hotter than a greenhouse in August. In the fiscal first quarter of 2027, revenue surged 85% higher year over year to nearly $82 billion, while headline net income more than tripled to over $58 billion.

Today's Change

(

0.54

%) $

1.21

Current Price

$

225.30

Simply put, Nvidia is the go-to chipmaker for the AI revolution. For many clients wanting to build out AI compute, the company's silicon isn't simply the best choice, it's the only choice. To my mind, as long as the AI revolution lasts, Nvidia's going to be right at the front of it.

The company's stock has become awfully expensive on both price and valuation. However, it conveys ownership of a business that's currently changing our world forever. I'd say that's worth a high premium, and I'd be a buyer of the stock regardless.

Nvidia's $0.25 per-share payout currently yields nearly 0.5%.

2. Taiwan Semiconductor Taiwan Semiconductor is the chip factory (or foundry, in industry parlance) to the global tech industry. It's far and away the leading third-party semiconductor maker, creating chips for a dizzyingly large list of clients around the globe -- including, importantly, Nvidia.

This is as successful a business as you'd expect. Reflecting this, in May the company declared a nearly 17% dividend raise, from 6 New Taiwan dollars ($0.19) per share to NT$7 ($0.22). This raise hasn't kicked in yet -- it takes effect with the payout slated to occur Oct. 8, for investors of record as of Sept. 16.

The company's recent growth has been almost Nvidia-like. In July alone, it earned revenue of NT$467.6 billion ($14.5 billion), which was nearly 45% higher year over year.

Last month, it published its Q2 results, revealing a 36% increase in net sales to NT$1.27 trillion ($39.5 billion) and a 77% gain in headline net income to NT$706.5 billion ($21.9 billion). Again, as with Nvidia, Taiwan Semi is a top choice for outsourced chipmaking, and with the explosion of AI, it's reaping the rewards.

Today's Change

(

0.31

%) $

1.34

Current Price

$

430.49

The only factor that would make me hesitant to own the company's stock is the possibility that Taiwan's political situation with China could worsen. Yet I feel there's at least some awareness in those nations that any major conflict could be ruinous to both.

Meanwhile, the stock is cheaper on a valuation basis than Nvidia and will boast a higher dividend yield on each of its U.S.-listed American Depositary Shares, at roughly 1% based on the current exchange rate.

3. Broadcom Broadcom distinguishes itself from its two chip industry peers by specializing in customization. It designs silicon with (and for) clients known as application-specific integrated circuits (ASICs), engineered for their particular needs.

Broadcom's customer lineup has plenty of famous names from the tech world. A leading example is its work with Alphabet's Google to develop that company's Tensor Processing Units (TPUs), which are considered among the most cutting-edge AI processors on the market.

Interestingly, in the often-circular AI industry, the TPUs that Google and Broadcom concoct are manufactured by Taiwan Semiconductor.

Broadcom began its current fiscal year (2026) with raising its quarterly dividend by just over 10% to $0.65 per share. It clearly -- and correctly -- anticipated that its recent double-digit increases in key fundamentals would be more than sufficient to fund the enhanced payout.

Today's Change

(

0.43

%) $

1.77

Current Price

$

417.82

The company's net revenue ballooned by 48% year over year to almost $22.19 billion in fiscal Q2, reported in June. It almost doubled headline net income, to over $9.31 billion from slightly under $4.97 billion.

Broadcom has found quite a large and lucrative niche in which to operate. This has, predictably, attracted competitors, most notably the smaller but very ambitious Marvell Technology. Yet analysts put Broadcom's market share at a commanding 55% to 60%, and in the high-stakes game of AI build-outs, players like to go with a company that's trusted by many to do the work. AI is also a rising tide that will lift all the sturdy boats, so I wouldn't worry if Broadcom's share dips a little.

The company most recently paid the $0.65-per-share dividend at the end of June. It yields 0.6%.

Key Takeaways Coinbase is expanding beyond spot trading through derivatives, global products and tokenization.COIN's Deribit integration aims to improve execution, liquidity and institutional trading infrastructure.Coinbase's Abu Dhabi tokenization hub could support issuance, custody, trading and settlement.
Coinbase Global’s (COIN - Free Report) growth story is increasingly extending beyond crypto prices and spot trading. The company is positioning itself as a global financial infrastructure platform for the next generation of markets through several strategic initiatives.

The integration of Deribit brings one of the world’s leading crypto derivatives platforms into Coinbase’s ecosystem. Now COIN is rolling out a new high-performance matching engine to enable faster execution, deeper liquidity, and the infrastructure demanded by sophisticated institutional traders. It also moves Coinbase closer to capturing a larger share of global derivatives activity.

Geographic expansion is another key growth driver. Coinbase has launched futures, perpetuals, and options for professional investors in the UK, providing institutional clients with access to a broader range of products. These offerings support the company’s evolution from a primarily crypto-focused exchange into a comprehensive, multi-asset trading venue.

Coinbase has also secured regulatory approval to establish an international tokenization hub in Abu Dhabi. This positions the company to participate in the migration of traditional financial assets onto blockchain infrastructure. Over time, tokenized securities could create substantial opportunities across issuance, custody, trading and settlement.

Together, these initiatives create a compelling growth narrative. Derivatives strengthen Coinbase’s trading engine, international expansion broadens its institutional reach, and tokenization opens a significant long-term market. COIN is steadily emerging as a core financial platform for the onchain economy.

What About Its Peers?Robinhood Markets (HOOD - Free Report) stays focused on accelerating growth through rapid product innovation and global expansion. Robinhood has been engaging in opportunistic acquisitions to deepen its footprint and expand its product reach within the United States and globally. Robinhood also noted that AI features and fast rollouts are increasing engagement, premium monetization and retention, while stronger tools attract both retail and advanced traders.

Interactive Brokers (IBKR - Free Report) continues to explore growth opportunities in the emerging markets of Taiwan, Mexico and India. Given the rapid growth of its European business, Interactive Brokers has substantially expanded its operations there. Interactive Brokers has been undertaking several measures to enhance its global presence.

COIN’s Price PerformanceShares of COIN have lost 33.5% in the year-to-date period, underperforming the industry.

Image Source: Zacks Investment Research

COIN’s Expensive ValuationCOIN trades at a price-to-earnings ratio of 67.86, significantly above the industry average of 17.05.

Image Source: Zacks Investment Research

Estimate Movement for COINThe Zacks Consensus Estimate for COIN’s third-quarter and fourth-quarter 2026 earnings per share (EPS) witnessed southbound movement in the last 30 days. The same holds true for 2026 and 2027.
 

Image Source: Zacks Investment Research

The consensus estimates for COIN’s 2026 revenues and earnings indicate year-over-year decreases. Nonetheless, the consensus estimates for 2027 revenues and earnings imply year-over-year increases.

COIN stock currently carries a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways WST's HVP Components sales rose 19.4%, while HVP Delivery Devices sales increased 29.6%.West raised 2026 organic sales growth guidance to 10%-11% and adjusted EPS to $8.85-$9.05.WST trades at 37.1X forward earnings, more than double its sub-industry's 17.8X multiple.
West Pharmaceutical Services, Inc. (WST - Free Report) shares have gained 17.2% in the past three months, ahead of the Zacks Medical sector's 18.9% rise and the S&P 500's 2% advance. The move reflects improving operating momentum, but valuation leaves less room for execution misses.

The central question is whether High-Value Product demand, margin expansion and a higher 2026 outlook can support further gains after the recent run.

Image Source: Zacks Investment Research

WST's HVP Mix Supports the RallyHigh-Value Product Components remain West's main growth engine. Second-quarter sales reached $424.1 million, up 19.4% year over year and 18.4% organically, representing 49% of total company sales.

Demand benefited from biologics, GLP-1 elastomers and customer upgrades to higher-quality containment solutions, including Annex 1-related conversions. NovaPure and FluroTec products were key contributors, while High-Value Product Delivery Devices sales increased 29.6% to $131.2 million.

Becton, Dickinson and Company (BDX - Free Report) is investing $110 million to expand U.S. production of prefillable syringes for biologic and GLP-1 drug delivery. AptarGroup, Inc. (ATR - Free Report) , another drug-delivery supplier, reported a 4% increase in Pharma sales in the second quarter, underscoring continued activity across injectable and advanced drug-delivery markets.

West's Q2 Beat Adds Fundamental SupportSecond-quarter revenues increased 13.8% to $872.3 million, while organic sales grew 12.7%. Adjusted earnings of $2.37 per share rose 28.8% and beat the Zacks Consensus Estimate by 13.9%.

Proprietary Products revenues climbed 16.6% to $722.6 million. Gross margin expanded 200 basis points to 37.7%, and adjusted operating margin improved 230 basis points to 22.6%, showing the earnings benefit from richer product mix and operating leverage.

WST's Raised Outlook Extends the Growth CaseWest raised its 2026 revenue outlook to $3.345 billion-$3.380 billion from $3.295 billion-$3.350 billion. Organic sales are now expected to increase 10%-11%, up from the prior 7%-9% range.

Adjusted earnings guidance rose to $8.85-$9.05 per share from $8.40-$8.75. Management now expects both GLP-1 and non-GLP-1 High-Value Product Components to grow in the high teens organically for the year, supporting continued mix improvement.

West's Premium Valuation Tests Further UpsideWST trades at 37.1X forward 12-month earnings, more than double the Zacks sub-industry's 17.8X multiple. The stock also trades above the Medical sector's 21.2X and the S&P 500's 20.7X.

The multiple is below WST's five-year median of 39.1X, but it still implies that investors are paying a sizable premium for growth and execution. Further appreciation may therefore require continued earnings delivery and sustained High-Value Product momentum.

Image Source: Zacks Investment Research

WST Risks Could Check the MomentumStandard Products sales increased just 2.4% in the second quarter, while West Vantage revenues rose 2% and only 0.8% organically. West Vantage was also affected by cyber-related production downtime, which pushed some revenues into the second half.

Higher oil and commodity costs remain another pressure point. The July 1 sale of SmartDose 3.5mL also creates a portfolio transition, while the Dublin drug-handling ramp and other operational initiatives add execution risk.

Wrapping UpWST's recent gain is supported by faster High-Value Product growth, wider margins and a stronger 2026 earnings outlook. Against that, the premium valuation and softer performance in Standard Products and West Vantage raise the threshold for additional upside.

Currently, West carries a Zacks Rank #3 (Hold). Likewise, Becton, Dickinson and Company, and AptarGroup also carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways JetBlue shares gained 22.2% in three months as improving revenue trends supported momentum.JetBlue expects 2026 RASM growth of 10-12.5%, while capacity is projected to increase 1.5-3.5%.JBLU faces higher fuel costs, about $8.48 billion in debt and a projected negative 2026 operating margin. JetBlue Airways Corporation (JBLU - Free Report) shares have gained 22.2% in the past three months, putting the durability of the rebound in focus. Better revenue trends and firmer earnings-estimate revisions have improved the near-term setup.

The rally still faces a demanding test. JetBlue remains unprofitable, fuel costs have climbed sharply and leverage is high, leaving further upside dependent on revenue gains translating into a clearer margin recovery.

JBLU’s Three-Month Gain Comes With Better MomentumJBLU’s 12-week price change of 22.2% is backed by a 3.4% gain over the past four weeks. The stock also carries a Momentum Score of A, the strongest of its individual Zacks Style Scores.

The move has occurred while JetBlue’s commercial performance improved. Second-quarter revenue per available seat mile, or RASM, increased 10.9% year over year, while capacity rose 3.2%, showing that unit revenues advanced faster than available seat miles.

JetBlue’s Earnings Revisions Are Moving HigherThe current-fiscal-year earnings estimate increased 7.7% over four weeks and 21.9% over 12 weeks. That direction is relevant because the Zacks Rank is driven by earnings-estimate revisions, giving the recent price momentum a firmer estimate backdrop.

JetBlue also posted a 5.7% earnings surprise in the second quarter. The result was still a loss of 66 cents per share, however, so upward revisions should be viewed as an improvement in expectations rather than proof that profitability has returned.

JBLU’s Revenue Outlook Supports the Bull CaseManagement expects third-quarter RASM to rise 12.5-16.5% year over year on capacity growth of 3-6%. For full-year 2026, JetBlue forecasts RASM growth of 10-12.5% while capacity is expected to increase 1.5-3.5%.

Premium and loyalty demand also matter in the broader airline backdrop. Delta Air Lines (DAL - Free Report) reported 17% growth in second-quarter premium-product ticket revenues, while United Airlines Holdings (UAL - Free Report) reported 14% first-quarter premium revenue growth. JetBlue’s own premium RASM rose about 13% in the second quarter.

JetBlue Still Faces Fuel and Leverage RisksSecond-quarter aircraft fuel expense surged 80.7% year over year to $911 million as the average fuel cost per gallon increased 76.3% to $4.23. Total operating expenses rose 20.8%, contributing to a $141 million operating loss.

Debt and financing costs add another constraint. Total debt was about $8.48 billion at June 30, 2026, while 2026 interest expense is expected to be about $590 million. JetBlue still projects a negative adjusted operating margin of 2-5% for the year.

JBLU’s Mixed Scores Temper the Rally CaseThe rally has better support than it did earlier, but the investment picture remains mixed. Stronger unit-revenue growth, positive estimate revisions and JetForward progress can sustain interest in the shares, while fuel volatility, losses and debt leave little room for execution slippage.

JBLU currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 Its Momentum Score of A contrasts with a Value Score of D, Growth Score of F and VGM Score of F. The combination favors patience: momentum is favorable, but the broader Style Score profile does not yet provide the kind of all-around confirmation associated with top-ranked stocks.